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Summary 
 
Idiopathic pulmonary fibrosis (IPF) is a devastating and lethal disease, with a 
median survival of 2-3 years after diagnosis. It is chronic, progressive and 
occurs predominantly in middle-age and older adults. Multiple working 
hypotheses speak of possible triggers of IPF development, e.g. multiple 
microinjuries of the alveolar epithelium, aberrant fibroblast activation, and 
immune deregulation. Currently, there are two drugs approved for the 
treatment of mild-to-moderate IPF worldwide, neither Pirfenidone or 
Nintedanib provide a definitive cure for disease, but slow in disease progression.  
Thus, animal models of pulmonary fibrosis are a critical tool for disease 
understanding, drug development and pre-clinical intervention.  
In chapter 2.1, the first study included in this thesis (Fernandez et al., 2016a), we 
comprehensively analyzed IPF-relevant peripheral biomarkers, histological 
compromise along with physiological parameters, to determine disease onset, 
progression and resolution in preclinical models of fibrosis. We observed and 
validated that the bleomycin-induced pulmonary fibrosis model reached its 
peak of fibrosis 14 days after treatment and from there on, resolution started. 
Furthermore, we created a semi-automatized histologic scoring system to 
quantify the degree of fibrosis, and correlated histology score with lung function 
decline during the initiation, peak and resolution phase of the model. 
Interestingly, we observed that at day 28 and 56 although histological 
compromise was still present, lung function was close to normal. Furthermore, 
we determine that plasma levels of ICAM-1 strongly correlate with the extent of 
fibrosis. We complemented and extended our characterization of the model 
further. In a following study, we performed multi-compartmental deep 
IX
 
proteomics in lung tissue and bronchoalveolar lavage (Schiller, Fernandez et al., 
2015), with emphasis on characterizing the matrisome, from the initiation to the 
resolution of bleomycin-induced fibrosis, in where we could determine the 
initial signatures of injury, as well as the ones that drive lung repair. 
In chapter 2.2, we highlighted the second study of this thesis (Sun et al., 2015), 
that goes along with a complementary publication of our authorship.   We use 
the ability of matrix-assisted laser desorption/ionization mass spectrometry 
imaging (MALDI-MSI) to simultaneously record the distribution of hundreds of 
molecules, in a highly multiplexed and unbiased manner. After oral 
administration of pirfenidone, we could detect, visualize, and quantify the 
pharmacokinetics and in-situ distribution of pirfenidone in lung, liver and 
kidney from unchallenged mice. Furthermore, we performed analysis in fibrotic 
mice and IPF patients, untreated and under pirfenidone therapy (Sun*, 
Fernandez* et al. 2018). As expected, we detected mouse and human specific 
and shared responses; specific alterations of metabolite pathways in fibrosis, 
and most importantly, metabolic recalibration following pirfenidone treatment. 
Taking together, bleomycin-induced pulmonary fibrosis is an extremely valuable 
tool for preclinical drugs evaluation, as well as for target validation and 
modulation of Idiopathic Pulmonary Fibrosis. 
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Zusammenfassung 
 
Die idiopathische pulmonale Fibrose ist eine schwerwiegende und tödlich 
verlaufende Erkrankung mit einer durchschnittlichen Lebenserwartung von 
zwei bis drei Jahren nach Diagnosestellung. Die chronisch progressive 
Erkrankung tritt vorwiegend im mittleren Lebensalter sowie bei älteren 
Erwachsenen auf. Zahlreiche Arbeitshypothesen zeigten mögliche Auslöser der 
IPF auf, wie beispielsweise Mikroverletzungen des Alveolarepithels, eine 
gestörte Fibroblastenaktivierung sowie eine Fehlregulation des Immunsystems. 
Derzeit sind weltweit zwei Medikamente zur Behandlung von leichter bis 
mittelschwerer IPF zugelassen, Pirfenidon und Nintedanib. Beide Medikamente 
verlangsamen den Verlauf der Erkrankung führen jedoch zu keiner Heilung. 
Somit sind Tiermodelle der Lungenfibrose ein wichtiges Werkzeug für das 
Verständnis von Krankheiten, die Arzneimittelentwicklung und präklinische 
Intervention. 
Kapitel 2.1 fasst die erste Publikation dieser Arbeit zusammen. In Fernandez et 
al. 2016 analysierten wir IPF-relevante periphere Biomarker und führten einen 
histologischen Vergleich mit physiologischen Parametern durch, um die 
Entstehung der Erkrankung, den Verlauf und die Resolution in präklinischen 
Modellen der Fibrose zu bestimmen. Unsere Ergebnisse zeigten, dass die 
Fibrose im bleomycininduzierten Modell der Fibrose ihren Höhepunkt an Tag 14 
nach Belomycinbehandlung erreichte und danach die Phase der Resolution 
begann. Wir generierten ein semi-automatisiertes histologisches 
Bewertungssystem um den Grad der Fibrose zu quantifizieren und korrelierten 
diesen Wert mit der Abnahme der Lungenfunktion während der 
Initiierungsphase, der maximalen Fibrose und der Resolutionsphase des Models. 
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Interessanterweise beobachteten wir an Tag 28 und 56 eine nahezu normale 
Lungenfunktion, obwohl histologische Auffälligkeiten noch immer vorhanden 
waren. Wir entdeckten, dass die Plasmaspiegel von ICAM-1 stark mit dem 
Fibrosegrad korrelierten. Wir erweiterten die Charakterisierung des 
Fibrosemodells und schlossen eine weitere Studie an, in der wir eine multi-
kompartmentelle tiefgehende Proteomanalyse von Lungengewebe und 
bronchoalveolären Lavagen durchführten. Der Fokus lag dabei auf der 
Charakterisierung des Matrisoms von der Initiierungs- bis zur Resolutionsphase 
der bleomycininduzierten Fibrose. Wir konnten die anfänglichen Signaturen der 
Verletzung bestimmen, sowie diejenigen, die die Lungenreparatur antreiben  
Kapitel 2.2 hebt die zweite Publikation der vorliegenden Arbeit hervor, Sun et 
al., 2015, der eine Koautorenschaft zugrunde liegt. Hierbei nutzten wir die 
Methode der Matrix–Assistierten Laser–Desorptions/Ionisierungs 
Massenspektrometrie Bildgebung (Imaging) (MALDI-MSI), welche es ermöglicht 
in einem multiplexen und ungezielten Ansatz simultan die Verteilung hunderter 
Moleküle zu messen. Nach oraler Gabe von Pirfenidon, visualisierten und 
quantifizierten wir die gemessene Pharmakokinetik und in situ Verteilung von 
Pirfenidon in Lunge, Leber und Niere von gesunden Mäusen. Zusätzlich 
analysierten wir fibrotische Mäuse und IPF-Patienten, unbehandelt als auch 
unter Pirfenidontherapie (Sun*, Fernandez* et al. 2018). Wie erwartet 
entdeckten wir sowohl maus- und menschspezifische als auch gemeinsame 
Reaktionen, bezüglich spezifischer Änderungen metabolischer Prozesse in 
Fibrose und, von besonderer Bedeutung, der metabolischen Neukalibrierung 
nach Pirfenidonbehandlung. Zusammengefasst ist das Tiermodell der 
bleomycininduzierten pulmonalen Fibrose ein wichtiges Werkzeug für die 
präklinische Arzneimittelbewertung, sowie für die Validierung potentieller 
Zielmoleküle und einer Modulation der idiopathischen pulmonalen Fibrose. 
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1. Introduction 
1.1. Idiopathic pulmonary fibrosis 
“IPF is defined as a specific form of chronic, progressive fibrosing interstitial 
pneumonia of unknown cause, occurring primarily in older adults, limited to the 
lungs, and associated with the histopathologic and/or radiologic pattern of 
UIP.” 
Definition by the Official ATS/ERS/JRS/ALAT Statement on Idiopathic 
Pulmonary Fibrosis (Raghu et al., 2011). 
1.1.1. Definition, epidemiology and clinical phenotypes 
Diffuse parenchymal lung diseases (DPLP) are a diverse group of clinical entities, 
where reversible or irreversible scaring and interstitial fibrosis of the lungs 
occur. So far, more than 150 causes of DPLD are recognized. For the majority of 
patients it is possible to identify a cause e.g. mold, bird exposure, or an 
underlying autoimmune disease. However, when no cause is identified, is 
considered as idiopathic interstitial pneumonia (IIP). Idiopathic pulmonary 
fibrosis (IPF) is the most common (55%) of all idiopathic interstitial pneumonias 
(Travis et al., 2013).  
Idiopathic pulmonary fibrosis is an orphan disease that affects subjects globally, 
even though its incidence varies among populations (Hutchinson et al., 2015). In 
Europe and North America, it is estimated conservatively around 3-9 per 100 
000 per year (Raghu et al., 2006). More specifically, Raghu et al. reported in US 
incidence according to broad or narrow diagnostic criteria adjusted by age of 
16.3, and 6.8 per 100 000 respectively. In another later study, Raghu et al. 
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reported an incidence up to 93.7 per 100 000 in people 65 years old or older 
(Raghu et al., 2014). While in Asia and South America (Brazil) IPF incidence is 
reported around 1.2 to 4 and 0.26 to 0.48 per 100 000 per year, respectively 
(Hutchinson et al., 2015). Regarding prevalence, the variability across 
populations persists. In North America, the estimated prevalence per 100 000 of 
the population for all genders fluctuates between 14.0 and 63.0 depending study, 
narrow or broad criteria. In Europe, it fluctuates between 1.25 and 23.4 per 100 
000 (Nalysnyk et al., 2012). In several studies in North America and Europe, 
prevalence is reported to be increasing. Yet, is unclear whether this 
phenomenon is due to a true increase in incidence or to an increase in disease 
detection.  
 
Figure 1. Heterogeneity of the natural history and clinical sub-phenotypes of IPF patients. 
Previous microinjuries during the asymptomatic period, contribute to disease development. At 
time of diagnosis and “onset of symptoms” IPF patients can take different clinical trajectories, 
either “rapid progressor”, “slow progressor” (Taken and adapted from King et al., 2011)  
 
IPF has a predilection for middle-aged and older subjects, largely males. The 
natural history of IPF is progressive, pernicious, and unpredictable with eventual 
death (Figure 1). It is reported that patients are diagnosed between 6 to 24 
months after initiation of symptoms. When diagnosed, prognosis is uncertain 
and there are several clinical sub phenotypes that have being described.  Some 
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patients have a rapid deterioration with a poor short-term prognosis, so called 
“rapid progressors”. Others present a slow deterioration with multiple acute 
exacerbation episodes, characterized by respiratory worsening, fever and 
infections-like symptoms due to unrecognized reasons that shorten their life 
expectancy (Figure 2), called “slow progressors”. And others present steady 
disease deterioration over years, called “stable” (Raghu et al., 2011) (King et al., 
2011). Based on that, median survival is estimated 3 to 5 years from diagnosis.  
This estimation is based on studies performed previous to approval of currently 
used therapies; therefore it might not reflect the present scenario.  
 
1.1.2. Pathobiological features 
1.1.1.1. Pathophysiology, molecular features and current hypothesis 
The direct cause of IPF is unknown. Subjects with genetic susceptibility and life-
long exposure to risk factors that develop disease account for up to a third of all 
patients. To date, while the key initiating triggers are unidentified, it is known is 
that pulmonary fibrosis develops as an abnormal response to various lung 
insults, triggering aberrant wound-healing, epithelial apoptosis and senescence, 
uncontrolled fibroblast proliferation and activation, excessive extracellular 
matrix deposition, and a fibrotic-related immune reaction. Several 
environmental risk factors and life-long exposures contribute to initiate 
microinjuries in the lung. These include familial susceptibility (Kropski et al., 
2015; Nogee et al., 2001), cigarette smoking (Baumgartner et al., 1997), 
environmental exposures (Baumgartner et al., 2000), chronic silent micro 
aspiration (Lee, 2014), chronic viral infection (Arase et al., 2008), mainly herpes 
virus infection (Lawson et al., 2008; Tang et al., 2003), among others. 
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Figure 2. Lesions in idiopathic pulmonary fibrosis. A) Normal lung appearance, with functional 
alveoli. B) Basal, subpleural disease distribution in with altered architecture; injured apoptotic 
epithelium with fibroblastic foci accumulation in the lung parenchyma (Taken from Fernandez 
I.E. et al 2012). 
 
IPF is a highly complex molecular disorder, where multiple lung structural 
players e.g. epithelial cells, fibroblast, mesenchymal cells together with innate 
and adaptive immune cells, interplay to impair organ function, enhance ECM 
deposition, and ultimately destroy the lung architecture. The epithelium and 
fibroblast have being the more extensively studied compartments in IPF.  
The alveolar epithelium is the first barrier line of the lung; as such it receives at 
first hand the noxious impacts of the environment. Providing first-defense 
against infections (e.g. bacterial and viral), foreign particles, etc. and by itself, is 
able to orchestrate the initiation of innate and adaptive immune responses 
(Camelo et al., 2014). In biopsies from IPF patients, the alveolar epithelium is 
described as aberrant and hyperplastic (Cavazza et al., 2010). Thus, it raised the 
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hypothesis that during the asymptomatic period, silent microinjuries of the 
alveolar epithelium might drive disease initiation in susceptible individuals. 
Among the biological mechanisms in epithelial cells that have being described 
altered in IPF are unfolded protein response, endoplasmic reticulum stress 
(Korfei et al., 2008), autophagy (Araya et al., 2013; Patel et al., 2012), senescence 
(Lehmann et al., 2017), ultimately leading to apoptosis and necroptosis (Lee et al., 
2018).  
Another crucial finding in IPF histology is the co-localization of areas of 
hyperplastic and apoptotic alveolar epithelial cells neighboring reticular areas of 
α-SMA positive myofibroblast, so called “fibroblastic foci”, a pathognomonic IPF 
lesion (Cool et al., 2006). These findings, along with multiple studies, support 
that epithelial damage activates fibroblasts, and induces fibroblast 
differentiation into myofibroblasts (Kendall & Feghali-Bostwick, 2014). 
Fibroblasts are the main support cell in all connective tissues. For maintaining 
parenchymal organization, they produce structural ECM proteins as collagens, 
elastins, laminins, fibronectin, glycosaminoglycans (Kendall & Feghali-Bostwick, 
2014). Fibroblast activation is key for homeostatic wound healing processes, and 
when activation is unrestrained it triggers myofibroblast differentiation, 
excessive ECM generation and deposition, inflammatory feed-back loops, bi-
directional epithelial-fibroblast activation, among other phenomena. Different 
cell types has been proposed as sources of activated fibroblast in fibrosis (Figure 
3), for instance pleural mesothelium, pericytes, resident quiescent fibroblast, 
fibrocytes, endothelial and epithelial cells, which upon injury would undergo 
epithelial- or endothelial-to-mesenchymal transition acquire mesenchymal 
markers, and contribute to the fibroblast pool. 
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Figure 3. Possible sources of fibroblast in the fibrotic lung. In the top, from left to right: 
epithelial cells, endothelial cells, fibrocytes, resident fibroblast, pericyte, mesothelial cells 
(Modified from Fernandez IE. et al, 2012). 
 
Growth factors, cytokines, chemokines and soluble mediators together with 
central pathway activation are of pivotal importance in IPF.  Pathways as WNT 
(Konigshoff et al., 2009), Sonic Hedgehog (Bolanos et al., 2012) and Notch (Hu et 
al., 2015), highly active in the developmental embryo get reactivated in highly 
proliferative diseases, as IPF (Selman et al., 2008). Transforming growth factor-ȕ 
(TGF-ȕ) is a master regulator and by far one of the most studied growth factors 
in fibrosis. When activated, TGF-ȕ plays pleiotropic functions like chemotactic 
and proliferation induction. While is critical for epithelial cells homeostasis, 
increased levels induce epithelial apoptosis and transformation of fibroblast into 
myofibroblast (Fernandez & Eickelberg, 2012).  
It is now clear that elements of the innate and adaptive immune response 
participate at several cellular and sub-cellular levels to myofibroblast 
differentiation and fibrogenesis (Desai et al., 2018). From the adaptive immunity 
angle, T cell role is complex and subset-dependent. Th1, Th22 and Ȗδ-T 
(Simonian et al., 2010) cells seem to attenuate lung fibrosis, while Th2 and Th17 
(Simonian et al., 2009) cells to promote it. Tregs (Kotsianidis et al., 2009) and 
Th9 subsets are controversial, and show both anti- and pro-fibrotic effects. 
From the innate immune cells angle contributions from new players as myeloid 
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derived suppressor cells (Fernandez et al., 2016b) and ILC2 (Lai et al., 2016), has 
been proposed, and the widely-studied M2 macrophages and neutrophils are 
known to enhance pulmonary fibrosis, whereas M1 macrophages show a 
protective role (Wynn & Vannella, 2016). Fibrocytes represent bone marrow-
derived immune cells that migrate to the lung differentiate into myofibroblasts 
to promote pulmonary fibrosis (Moeller et al., 2009). Altogether, these reports 
suggest that an immunosuppressive network affect and shift the phenotype and 
function of immune cells in IPF, suggesting that an immunosuppressive 
environment operates in the peripheral blood and lungs and might influence 
disease progression. Indeed, the putative downregulation of protective immune 
pathways could, at least partially, explain the failure of the PANTHER-IPF 
clinical trial, in which IPF patients who received immunosuppressive agents had 
worse outcomes (Idiopathic Pulmonary Fibrosis Clinical Research et al., 2012). 
 
 
Figure 4. Innate and adaptive immune cells as fibrosis modulators. (Taken from Kolahian S. Et 
al, 2016) 
1.1.1.2. Genetic determinants 
Advances in genomic techniques have allowed major progress in unraveling the 
genetic landscape of IPF patients. Three key genome-wide association studies 
(GWAS) (Allen et al., 2017; Fingerlin et al., 2013; Noth et al., 2013) identified 
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single-nucleotide polymorphisms (SNPs) associated with IPF susceptibility, in 
the Mucin 5B (MUC5B) and toll-interacting protein (TOLLIP). Polymorphism in 
the promoter region of MUC5B (rs35705950) is associated with a higher 
likelihood of developing IPF (Peljto et al., 2013). MUC5B is localized in areas of 
microscopical honeycombing, and honeycomb cysts (Seibold et al., 2011).  
Although patients carrying this allele have higher risk of disease, they concur 
with milder course and longer survival. To date, the precise role of MUC5B in 
the pathophysiology of IPF is unclear.  
Variants in TOLLIP are not only associated with susceptibility, but also with 
treatment responses in IPF.  The SNP rs5743890 within TOLLIP gene is 
associated with increased mortality risk (Noth et al., 2013), and rs3750920 with 
better response to N-acetylcysteine therapy (Oldham et al., 2015).  
Genetic variations also include an autosomal dominance inheritance that lead to 
familial forms of disease. In IPF telomerase mutations and shortening, show a 
strong relationship in relatives with Familial IPF. Recently, genetic evaluations of 
IPF patients and affected relatives, confirmed the relationship with telomerase 
mutation (Kropski et al., 2017) and shortening (Stuart et al., 2015). Other studies 
have reported that familial forms are associated with variances of TERT, TERC 
(hTR), DKC1, TINF2, RTEL1, and PARN, as well as mutations in surfactant proteins 
SP-A, SP-D, and ABCA3 genes (Epaud et al., 2014; Kropski et al., 2017). 
1.1.3. Diagnosis and clinical features 
Clinically, patients consult with non-specific symptoms and typically debut with 
breathlessness on exertion, which can or cannot be accompanied by dry cough. 
Unless IPF is suspected, this unspecific presentation delays proper and timely 
diagnosis. At physical examination bibasilar expiratory crackles (rales) are often 
found (Cottin & Cordier, 2012), together with finger clubbing in about 50% of 
patients (Kanematsu et al., 1994). On spirometry, a restrictive defect in lung 
function and abnormal gas exchange are preset. Furthermore, it is characterized 
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by a reduced forced vital capacity and total lung capacity, and a reduction in 
diffusing capacity of the lung for carbon monoxide (DLco).  
IPF is associated with a specific radiological and/or histopathological pattern of 
usual interstitial pneumonia (UIP), consider the hallmark of IPF diagnosis. Along 
with the exclusion of other causes of interstitial fibrosis, e.g. connective tissue 
disease, adverse effect of medication, granulomatous diseases, among others, 
the diagnosis is made of combination of clinical diagnostic criteria, high-
resolution computed tomography (HRCT) scan, and biopsy (when required), in a 
multidisciplinary consensus between pulmonologist, radiologist, pathologist, 
rheumatologist, and in some cases thoracic surgeons.  
Radiologically, a HRCT pattern of UIP consists of reticular opacities, traction 
bronchiectasis and honeycombing, usually bibasilar and subpleural (Figure 5). 
Other features as reactive mediastinal and linear lymphadenopathy are also 
present. Ground-glass opacities are not exclusive of a UIP patter, but can be 
found. Based on radiological evaluation the HRCT can be classified as definite 
UIP, possible IPF or inconsistent.  
 
 
 Figure 5. HRCT images from IPF. High-resolution CT (HRCT) images collected from a woman 
with progressive cough and dyspnea, showing her upper lung zones (panel a), lower lung zones 
(panel b) and the sagittal plane of the lungs (panel c). These images show lower lobe-
predominant peripheral honeycomb change (panels b and c, arrows), which is typical of the 
usual interstitial pneumonia (UIP) pattern.  (Modified from Martinez, F. J. et al. 2017) 
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Due to increased mortality risk, open lung biopsy is no longer gold standard for 
IPF diagnosis. However, when imaging is inconclusive, biopsy is recommended. 
Histologically, a pattern of UIP consist of patchy and heterogeneous 
distribution, with architectural destruction at low magnification areas, 
alternating between fibrosis, scaring and honeycombing, with less affected areas 
of “normal” appearance (Figure 6). These areas are usually sub-pleural and 
paraseptal. Fibrotic zones are characterized for dense accumulation of 
extracellular matrix, and fibroblast bundles, so called “fibroblastic foci”, located 
in vicinity of hyperplastic type 2 epithelial cells. Honeycomb regions are 
composed by cystic spaces lined by hyperplastic and aberrant bronchial 
epithelium.  
  
 
Figure 6. Histological UPI pattern from IPF. A) normal lung histology. B) Low-power H&E from 
a patients with UIP, revealing honeycombing, a characteristic of usual interstitial pneumonia 
(UIP) pattern, with of subpleural cystic airspaces, and well-defined walls.  C) High-power H&E 
from the lung biopsy in “B”, confirming the presence of fibroblastic foci (arrow) (Modified from 
Martinez, F. J. et al. 2017) 
1.1.4. Biomarkers 
To-date there is no molecular biomarkers in widespread use for IPF. There are 
several exciting candidates under study, yet none of them has reached clinical 
practice use internationally. Currently, imaging through detection of interstitial 
lung abnormalities (ILA) are the closest attempt of early detection of fibrosis 
(Sack et al., 2017; Washko et al., 2011). In IPF there a tremendous unmet need in 
stablishing markers for disease early diagnostics, progression and outcome (Ley 
et al., 2014), hence, several groups have focused their research on developing 
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and establishing these signatures (Table 1). KL-6 (Yokoyama et al., 2006), CCL-18 
(Prasse et al., 2009), and SP-A (Greene et al., 2002) were some of the ﬁrst 
molecules proposed as biomarkers in pulmonary ﬁbrosis. KL-6 was analyzed 
retrospectively in a cohort of 27 patients, revealing that elevated serum levels 
(>1000U/ml) could predict survival, and acute exacerbations (Collard et al., 
2010). When compared with clinical parameters (age, FVC, DLco and FVC 
change), high levels of KL-6 did not improve prediction of survival (Song et al., 
2013). CCL18, a chemoattractant produced in alveolar macrophages, was found 
to predict outcome in a cohort of 72 patients, where 6-month follow-up study 
increased levels of CCL18 correlated with FVC and TLC decline. Recently in both 
CAPACITY 1 and 2, and ASCEND trials plasma concentrations of CCL18 were the 
most consistent predictor of progression, studied in a IPF trial to study 
treatment response (Neighbors et al., 2018). SP-A also showed potential of 
mortality prediction in the serum from 82 patients. (Song et al., 2013). 
Other proposed biological markers relate to ECM turnover e.g. matrix 
metalloprotease 7 (MMP7) (Bauer et al., 2017; Rosas et al., 2008; Tzouvelekis et 
al., 2017), collagen degradation products (Jenkins et al., 2015), ECM-related 
autoantibodies (Li et al., 2017), epithelial signatures (Maher et al., 2017). For the 
focus of this thesis, is important to highlight a study by Richards et at. where 
combining clinical parameters and plasma protein concentrations, the authors 
could distinguished high and low mortality risk subgroups, an could accurately 
predict mortality. In this study 92 proteins were measured in plasma from 241 
IPF patients (140 for derivation and 101 for validation cohort), reporting a poor 
overall survival prediction by elevated levels of MMP7, ICAM1, IL8, VCAM1, and 
S100A12 in both discovery and derivation cohort. ICAM1 was the only predictor 
of poor survival in the validation cohort, all five proteins were correlated with 
poorer transplant-free survival (Richards et al., 2012). Taken together, these data 
show that predicting IPF outcome might be feasible by combining clinical data 
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and peripheral blood biomarkers. Further studies in broader populations need to 
establish the reliability of these markers in routine clinical settings. 
1.1.5. Treatment  
In 2011, the antifibrotic agent Pirfenidone was first approved in Europe and 
Japan, for the treatment of IPF followed by US approval in 2014. Nintedanib, was 
then concomitantly approved worldwide as IPF therapy (Karimi-Shah & 
Chowdhury, 2015).  
Nintedanib is a kinase inhibitor, initially developed as an anticancer agent. It 
blocks the downstream effect of growth factors implicated in fibrosis, including 
the receptors for vascular endothelial growth factor, fibroblast growth factor 
and platelet-derived growth factor (Wollin et al., 2015). Two phase 3 trials 
(INPULSIS-1 and INPULSIS-2) were reported in May 2014. Nintedanib-treated 
group had a significant reduction in FVC decline, when compared to placebo, 
reducing also the recurrence of acute exacerbations (Richeldi et al., 2014). 
Pirfenidone was the first drug licensed specifically for IPF. To-date the exact 
mechanism of action of pirfenidone remains unclear. However, evidence shows 
that exerts anti-fibrotic, anti-inflammatory and antioxidant effects (Schaefer et 
al., 2011). Molecularly, treatment with pirfenidone reduces fibroblast production 
of fibronectin, α-SMA, collagen 1, collagen V and collagen fibril formation 
(Knuppel et al., 2017; Lehtonen et al., 2016).  The beneficial effects of pirfenidone 
were first observed in 1999, and got the approval after multiple preclinical 
testing and four phase 3 trials (Poletti et al., 2014). The results reported by the 
first 3 trial were not concordant.  CAPACITY 2, ASCEND, and the Japanese trial, 
found that pirfenidone significantly reduced FVC compared with placebo, 
slowing disease progression, but CAPACITY 1 study did not show similar results 
(Noble et al., 2011). To clarify the lack of reproducibility, a Cochrane meta-
analysis of these three trials was done and showed that pirfenidone significantly 
reduced the risk of disease progression (Spagnolo et al., 2010). Then, in ASCEND 
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pirfenidone significantly improved progression-free survival, and slowed FVC 
decline, confirming the results from CAPACITY 2 (King et al., 2014). 
Both dugs are recommended for use as IPF therapy by all worldwide thoracic 
societies (Raghu et al., 2015), and currently under consideration for combination 
therapy (Flaherty et al., 2018; Rajchgot et al., 2018). At present, treatment of IPF 
is transforming quickly, with the highest aim to hopefully one-day reverse 
disease. 
 
1.2. Modeling pulmonary fibrosis in mice 
For modeling IPF, scientist have used different approaches, substances like 
bleomycin, silica (Davis et al., 1998), or fluorescein isothiocyanate (FITC) 
(Christensen et al., 1999), irradiation (Haston & Travis, 1997), gene manipulation 
(Sime et al., 1997), cytokine overexpression (Kolb et al., 2001), and is still much 
missing to fully mimic the human scenario. It is widely accepted that the current 
animal models do not adequately replicate the pathophysiological features of 
IPF (Jenkins et al., 2017). Ideally, the perfect animal model would recreate the 
characteristic histological features of UIP, be progressive or at the least 
irreversible, applicable across mouse strains, reproducible, and if possible, be 
performed in a reasonably short time.  
Nevertheless, these models have been extremely useful for identifying pathways 
leading to lung fibrosis, including those involving TGF-ȕ, connective-tissue 
growth factor, fibroblast growth factor, platelet-derived growth factor, 
microRNAs, reactivation of developmental pathways, MMP-7, among others.  
1.1.2. The bleomycin-induced pulmonary fibrosis model 
Bleomycin is a chemotherapeutic agent used for cancer treatment (Evans et al., 
1982). Pulmonary toxicity is one of the side effects, which can be life threatening 
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(Catane et al., 1979). Bleomycin induces DNA breaks that produce oxidative 
damage and injures the lungs due to lack of bleomycin hydrolase, an enzyme 
that inactivates the drug (Claussen & Long, 1999; Jules-Elysee & White, 1990).  
With its advantages and disadvantages, bleomycin induced-pulmonary fibrosis is 
consider “the best-characterized animal model available for preclinical testing” 
(Jenkins et al., 2017). By far, it has being the most studied model for IPF research, 
from different administration routs (e.g. intratracheal, oropharyngeal, 
subcutaneous, intravenous) to different strains, dosage and administration 
frequency (Degryse et al., 2010).  
The comparison between bleomycin-induced pulmonary fibrosis and IPF has 
been, and will always be, highly controversial. Nevertheless, many studies show 
strong similarities at many levels, ratifying the continuous use for preclinical 
testing (Bauer et al., 2015). At first, the inflammatory phase takes place within 
the first 7 days, followed by increased ECM deposition with a maximum at day 
14, and resolution from day 21-28 onward. Largely, lung function returns to basal 
levels at 56 days post bleomycin treatment(Moore & Hogaboam, 2008). In mice, 
the lesions induced by bleomycin are heterogeneous, time-limited and self-
resolving, with the disadvantage of a narrow time window for preclinical testing. 
From another angle, it offers the advantage of analyzing the dynamics of injury-
fibrosis-resolution and assesses heterogeneity in an intraindividual manner.  
To-date the most popular endpoints in pre-clinical models of IPF are 
histological scoring and lung collagen content (Carrington et al., 2018). However, 
in IPF patients the used endpoints are imaging and pulmonary function tests. 
Therefore, we propose that examining more clinically relevant endpoints in pre-
clinical models would provide better indication of treatment efficacy, in a more 
clinically relevant setting. 
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1.3. Objectives 
Despite advances in understanding the molecular mechanisms, genetic 
influence, and clinical features of idiopathic pulmonary fibrosis, there are 
several unmet needs. Currently, there is no available clinically approved 
biomarker that improves disease accuracy, reflects disease course, or predicts 
prognosis. Furthermore, the two drugs available for treatment of IPF patients, 
pirfenidone and nintedanib, slow down functional decline and disease 
progression, but are not yet curative. Remaining lung transplantation as the only 
curative treatment with a median survival of 5 about years and accessible only 
to highly selected patients.  
The aims of this thesis were to comprehensively analyze the bleomycin-induced 
pulmonary fibrosis model in order to: first, design tools for biomarker discovery 
and clinical assessment of the model; second, improve preclinical drug 
evaluation in mice. These results may reflect in an increase knowledge in the 
model, and hopefully in more successful drug approvals and clinical trial 
performances.  
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Fernandez IE, Amarie OV, Mutze K, Königshoff M, Yildirim
AÖ, Eickelberg O. Systematic phenotyping and correlation of bio-
markers with lung function and histology in lung fibrosis. Am J
Physiol Lung Cell Mol Physiol 310: L919–L927, 2016. First pub-
lished March 18, 2016; doi:10.1152/ajplung.00183.2015.—To date,
phenotyping and disease course prediction in idiopathic pulmonary
fibrosis (IPF) primarily relies on lung function measures. Blood
biomarkers were recently proposed for diagnostic and outcome pre-
diction in IPF, yet their correlation with lung function and histology
remains unclear. Here, we comprehensively assessed biomarkers in
liquid biopsies and correlated their abundance with lung function and
histology during the onset, progression, and resolution of lung fibro-
sis, with the aim to more precisely evaluate disease progression in the
preclinical model of bleomycin-induced pulmonary fibrosis in vivo.
Importantly, the strongest correlation of lung function with histolog-
ical extent of fibrosis was observed at day 14, whereas lung function
was unchanged at days 28 and 56, even when histological assessment
showed marked fibrotic lesions. Although matrix metalloproteinase-7
(MMP-7), MMP-9, and PAI-1 were significantly elevated in
broncheoalveolar lavage of fibrotic mice, only soluble ICAM-1 (sI-
CAM-1) was elevated in the peripheral blood of fibrotic mice and was
strongly correlated with the extent of fibrosis. Importantly, tissue-
bound ICAM-1 was also elevated in lung homogenates, with promi-
nent staining in hyperplastic type II alveolar epithelial and endothelial
cells. In summary, we show that lung function decline is not a
prerequisite for histologically evident fibrosis, particularly during the
onset or resolution thereof. Plasma levels of sICAM-1 strongly cor-
relate with the extent of lung fibrosis, and may thus be considered for
the assessment of intraindividual therapeutic studies in preclinical
studies of pulmonary fibrosis.
interstitial lung diseases; pulmonary fibrosis; lung injury and repair;
monitoring; outcome; surveillance
REPETITIVE LUNG INJURY FREQUENTLY induces lung fibrosis (13),
which leads to impairment of the alveolar-capillary units,
enhances fibroblast proliferation and extracellular matrix
(ECM) deposition, and aberrant repair processes. These pro-
cesses ultimately cause irreversible scarring of the lung, often
resulting in idiopathic pulmonary fibrosis (IPF) (3, 12). IPF is
a rapidly progressive and deadly disease with a median sur-
vival of 2–3 yr after diagnosis. Although two drugs (nintedanib
and pirfenidone) have been recently approved for mild-to-
moderate IPF in Europe and the United States, these slow
down the progression of IPF but are unable to reverse or cure
it (18, 29). To date, the clinical evaluation of IPF most
commonly relies on repeated physiological lung function mea-
surements [e.g., forced vital capacity (FVC), lung CO diffusing
capacity (DLCO)] and radiological findings on high-resolution
computed tomography and, when available, histopathology
(27). It is currently unclear, however, which of these parame-
ters best correlates with disease progression in IPF (40, 41).
Importantly, the survival of patients with interstitial lung dis-
ease significantly differs, even when comparing groups with a
similar decline in lung function [as assessed by FVC or forced
expiratory volume in 1 s (FEV1)] (38), suggesting that the
additional use of predictive biomarkers will more accurately
project the disease course. As such, defining sensitive pa-
rameters that assess and predict the progression of lung
fibrosis is imperative, in particular by systematically eval-
uating recently suggested blood biomarkers compared with
lung function and histology (5). To begin to address this
question, we addressed biomarker profiles in the widely
used bleomycin model of lung fibrosis in an effort to
adequately and precisely correlate biomarkers with physio-
logical and pathological parameters (33).
The assessment of drug efficacy in animal models of lung
fibrosis has been criticized recently, because several drugs
showed efficacy in animal models but not in clinical studies in
IPF. It is important to note, however, that the evaluation of animal
models is, in many cases, biased by reader-dependent measure-
ments (23). One particular challenge, for example, is the interin-
dividual heterogeneity of fibrosis in response to bleomycin, for
which it should be systematically accounted (22). Furthermore,
systemic evaluation of the bleomycin model is currently limited to
biochemical assays, biased selection of fibrosis-affected areas, or
reader-dependent scoring of histology sections (e.g., Ashcroft
score). Hence, more quantitative assessment of fibrosis or better
selection criteria in preclinical testing will be critical for drug
efficacy evaluation in these models.
Recently, a large prospective biomarker study showed that
VCAM-1, matrix metalloproteinase-7 (MMP7), ICAM-1, and
IL-8 are strong predictors of survival in IPF and might thus aid
in disease monitoring. Their correlation with lung histology,
however, remains unclear (28). Furthermore, a large retrospec-
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tive IPF cohort study demonstrated that all current available
models and commonly measured variables (e.g., FVC, dyspnea
score, and 6-min walk distance) failed to accurately predict phys-
iological and functional progression of IPF (19). Thus we sought
to assess these biomarkers in several compartments [broncheoal-
veolar lavage fluid (BALF), peripheral blood] during the initia-
tion, establishment, and resolution of fibrosis, and comprehen-
sively correlated their levels with histology and lung function to
better define the disease state and severity of lung fibrosis. Finally,
we performed serial blood measurements of soluble ICAM-1
(sICAM-1), the best performing biomarker in our study, and
assessed its expression and localization in the lung and primary
alveolar epithelial cells during injury and fibrosis.
METHODS
Animals. Pathogen-free female C57BL/6 mice (10–12 wk old)
were obtained from Charles River Laboratories and maintained at
constant temperature and humidity with a 12:12-h light-dark cycle.
Animals were allowed food and water ad libitum. All animal exper-
iments were conducted under strict governmental and international
guidelines and were approved by the local government for the admin-
istrative region of Upper Bavaria (TVA 55.2-1-54-2532-21-12), as
previously described (17).
Induction and assessment of pulmonary fibrosis. Pulmonary fibro-
sis was initiated by a single intratracheal instillation of 50 l of
bleomycin (3 U/kg, Sigma Aldrich, Taufkirchen, Germany) dissolved
in sterile PBS, and applied using the MicroSprayer Aerosolizer
(Model IA-1C; Penn-Century, Wyndmoor, PA). Control mice were
instilled with 50 l of PBS. After 7, 14, 28, or 56 days after bleomycin
or PBS instillation, lung function was measured using the FlexiVent
system (Sireq), and mice were sacrificed for biochemical and histo-
logical analysis. Bronchoalveolar lavage (BAL) was performed by
instilling the lungs with 3  0.5-ml aliquots of sterile PBS to obtain
BALF for biomarker analysis, and total/differential cell counts for
inflammatory cell recruitment of neutrophils, macrophages, or lym-
phocytes were measured. Lung tissue was either snap-frozen in liquid
nitrogen to determine tissue mRNA/protein expression or fixed by
intratracheal instillation of 4% paraformaldehyde and embedded into
paraffin for staining.
Image acquisition, processing, and analysis. At least three sections
from the same lung were cut and arranged on the same paraffin block,
and the slides were stained with hematoxylin-eosin (H&E). Stained
sections were automatically scanned with a digital Mirax slide scanner
system (3DHISTECH, Budapest, Hungary) equipped with a 20
objective with a numerical aperture of 0.75. The actual scan resolution
(effective pixel size in the sample plane) at 20 was 0.23 m. The
accompanying software allowed the user to navigate through the
captured Whole Slide Image (Zeiss, Germany).
Quantification of fibrosis using semiautomated image analysis. A
minimum of three whole-lobe cuts of 500 m from identical mice
were exported in high-quality .tif files (8). All images were analyzed
using an already developed macro (15), which required ImageJ v1.38
software or higher. This ImageJ macro was written to quantify the
percentage of fibrosis compared with the total amount of tissue within
an image. This percentage was determined by quantifying the total
tissue areas occupied by dense parenchyma. The threshold was set
arbitrarily after the black and white conversion to 5 (205) for all
slides. To do so, we converted the image from color to 8-bit, followed
by the delimitation of the area of interest (whole lobe selection) and
measurement of the selected area (Fig. 2A) as density percentage. The
alveolar space was determined by “parenchymal-free” area quantifi-
cation, which included bronchi and vessels (Fig. 2B). We then
quantified at least three sections (2 mm approximate distant from each
other in a transversal cut) from each lung; this value was averaged and
assigned as the percentage of alveolar space of each individual.
Luminex multiplex assay and ELISA. A multiplex biometric
ELISA-based immunoassay was performed using plasma or BALF
from PBS- or bleomycin-treated mice according to the manufacturer’s
protocols. We used the Mouse Cardiovascular Disease (CDV) panel 1
commercially available multiplex kit from Millipore (Billerica, MA).
MMP-7 and sICAM-1 ELISAs were performed using plasma, BALF,
or ATII supernatants from PBS- or bleomycin-treated mice, according
to the manufacturers’ protocol (Uscn Life Science, Wuhan, China;
Thermo-Scientific, Rockford, IL, respectively).
Immunofluorescent stainings. Lung tissue was embedded in paraf-
fin and immunofluorescence analysis was performed as previously
described (37). Briefly, sections were stained with anti-mouse
ICAM-1 (Thermo Fisher Scientific) or E-cadherin (Millipore) over-
night at 4°C, washed three times with PBS, and subsequently incu-
bated with the secondary antibodies (1:250 dilutions of Alexa Fluor
568 goat anti-rabbit or Alexa Fluor 488 goat anti-mouse) and 4=,6-
diamidino-2-phenylindole (DAPI, 1:2,000; Sigma-Aldrich, St Louis,
MO) for 1 h at room temperature. Finally, the sections were washed
three times with PBS and mounted in fluorescent mounting medium
(Dako). Images were acquired with an LSM 710 microscope (Zeiss)
operated in multitrack mode.
RNA isolation and real-time quantitative reverse-transcriptase
PCR analysis. RNA extraction from mouse tissue was performed using
the Roti Quick Kit (Carl Roth, Karlsruhe, Germany), followed by RNA
purification with the peqGold RNA isolation kit (Peqlab, Erlangen,
Germany), according to manufacturers’ instructions. Quantitative real-
time PCR (qRT-PCR) was performed using the SYBR Green PCR
master mix (Roche Applied Science, Mannheim, Germany).
Immunoblotting. Pulverized mouse tissue was homogenized in
Radio-Immunoprecipitation Assay (RIPA) buffer containing a pro-
tease and phosphatase inhibitor cocktail (Roche). Protein concentra-
tions were determined using the Pierce BCA Protein Assay (Thermo
Fisher Scientific). Samples were denatured in Laemmli buffer, resolved
by SDS-PAGE, and transferred to polyvinylidene diflouride membranes.
Nonspecific membrane binding was blocked with 5% low-fat milk in
0.1% Tween 20, TBS (TBS-T). Membranes were incubated with the
primary antibodies to ICAM-1 (Thermo Fisher Scientific) or -actin
(Sigma Aldrich) overnight at 4°C. After washing with TBS-T, the
membranes were incubated with secondary antibodies for 1 h at room
temperature. Blots were rinsed with TBS-T and visualized with the
enhanced chemiluminescence system (Thermo Fisher Scientific,
Waltham, MA), followed by analysis using the ChemiDocXRS imag-
ing system (Bio-Rad, Munich, Germany). Band quantification was per-
formed using ImageJ software (version v1.38).
Primary murine ATII cell isolation and culture. Primary murine
ATII (pmATII) cell isolation from PBS- or bleomycin-treated mice
was performed as previously described (24). Supernatants were col-
lected and snap-frozen; 1:2 diluted supernatants were used for the
assessment of sICAM-1 levels by ELISA.
Statistical analysis. Results are presented as means  SD and were
considered statistically significant at P  0.05. Data of selected
groups were compared using one-way ANOVA, followed by Dun-
nett’s post hoc test. The Pearson’s correlation coefficient (r value) was
used to determine the degree of association between variables and
interpreted using Dancey and Reidy’s categorization (9). Here, r
values of 1, 0.7 to 0.99, 0.4 to 0.69, 0.1 to 0.39, and 0
were interpreted as perfect, strong, moderate, weak, or no correlation,
respectively. The statistical significance of the correlations was as-
sessed by P value. A linear regression analysis between two variables
was performed and the best fit curve drawn from data points.
RESULTS
The dynamics of lung injury, fibrosis, and resolution in
bleomycin injury. We first sought to perform an extensive
phenotypic characterization of the bleomycin-induced fibrosis
model over an extended time period up to 56 days after
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intratracheal application of bleomycin. Lymphocyte and neu-
trophil cell numbers significantly increased in BALF during the
first 7 days after bleomycin injury and returned to baseline
levels after 28 days. BALF macrophage numbers, in contrast,
were significantly increased at all time points (day 7 to day 56)
and peaked 14 days after bleomycin injury (Fig. 1A). Static
lung compliance, a surrogate of tissue stiffness, was signifi-
cantly decreased 7 days postbleomycin, with a major decrease
14 days after bleomycin instillation. Static compliance returned
to baseline levels at day 28 and was significantly increased at
day 56 (Fig. 1B). Similar observations were made for tissue
elastance (Fig. 1B). Histological analysis revealed a peak of
lung fibrosis at day 14 after injury, which regressed, but did not
completely resolve, by day 56 (Fig. 2A).
To avoid reader-dependent bias, we designed a semiautoma-
tized algorithm to calculate the percentage of alveolar space
(Fig. 2B). After measuring 39 individual mice, including 29
bleomycin-injured mice (n  8, 9, 5, and 7 for days 7, 14, 28,
and 56 after bleomycin application, respectively) and 10 con-
trols (harvested from all time points, for a total of 149 images),
we observed a significant drop in alveolar space at day 7
compared with controls. The percentage of alveolar space
remained reduced over the entire observation period of 56 days
(Fig. 2C). We then assessed the correlation strength of the
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Fig. 1. Inflammatory cell recruitment and lung
function during lung fibrosis. C57BL/6 mice
(aged 10–12 wk, female) were treated with
bleomycin or PBS and harvested at days 7, 14,
28, or 56 after treatment. PBS represents a
pool of PBS-treated mice for 7, 14, 28, and 56
days. A: differential cell counts of inflamma-
tory cells were assessed in bronchoalveolar
lavage fluid (BALF). B: tissue stiffness was
determined by lung function measurement of
compliance and elastance. Data are presented
as means  SD; for statistical analysis, one-
way ANOVA was used. For all experiments
*P  0.05, **P  0.01, and ***P  0.001.
Macs, macrophages; Lymph, lymphocytes;
Neutro, neutrophils.
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Fig. 2. Semiautomatized quantification of
lung fibrosis. Hematoxylin-and-eosin (H&E)
staining of mouse lung sections from day 7,
14, 28, or 56 after treatment were scanned,
analyzed, and quantified with Image J soft-
ware. PBS represents a pool of PBS-treated
mice for 7, 14, 28, and 56 days. A: represen-
tative Masson trichrome stainings from PBS-
or bleomycin-treated mice are depicted. B:
threshold settings, 8-bit conversions, and area
selections of H&E stainings are shown. C:
quantification of alveolar space via Image J
software throughout the bleomycin time
course is shown. Each dot represents the
mean quantification of at least three whole-
lobe sections per subject. Statistical differ-
ences (*P  0.05, **P  0.01, and ***P 
0.001) were determined by one-way ANOVA.
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percent of alveolar space with lung function parameters (com-
pliance) using all samples at all time points. We observed a
moderate positive correlation (r  0.4) for all samples ana-
lyzed (Fig. 3A). When single time point correlations were
performed, we observed the strongest correlation at day 14
after treatment, followed by day 7 (Fig. 3B). No significant
correlations were obtained at day 28 or day 56. This indicated
that lung function parameters fully recovered to normal values
even in the clear presence of histological evidence of fibrosis.
To substantiate these observations, we measured transcript
levels of established markers of fibrosis collagen-1a1 (col1a1),
fibronectin (fn1), lysyl oxidase L2 (loxl2), and tenascin c (tnc)
in lung homogenates over the entire time course. We observed
a significant increase in all fibrosis markers during the peak of
lung fibrosis (day 14) compared with controls (Fig. 4), albeit
with different expression dynamics over the entire time course
of lung fibrosis. In fact, col1a1 was exclusively upregulated at
day 14 posttreatment, whereas fn1 was significantly upregu-
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Fig. 4. The mRNA expression patterns of
extracellular matrix markers in lung fibrosis.
The quantitative RT-PCR analysis of expres-
sion levels of collagen-1a1 (col1a1), fi-
bronectin (fn1), lysyl oxidase L2 (loxl2), and
tenascin c (tnc) from PBS- and bleomycin-
treated mice harvested 7, 14, 28, and 56 days
after treatment. PBS represents a pool of
PBS-treated mice for 7, 14, 28, and 56 days.
Data are presented as means  SD as 1-	CT
relative expression to control (GAPDH). Sta-
tistical differences (*P  0.05, **P  0.01,
and ***P  0.001) were determined by one-
way ANOVA.
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lated from day 14 until day 28. Expression of the ECM-
modifying enzyme loxl2 was increased from day 7 to day 28,
and decreased back to basal levels at day 56. Expression of tnc
was highly increased at day 7, which was maintained up to day
56. These dynamics thus suggest different contributions of
these ECM components to injury and scar formation in the
lung.
Compartmentalized biomarker signatures during lung in-
jury, fibrosis, and resolution. Next, we assessed protein ex-
pression using a five-analyte panel containing MMP-9, PAI-1,
E-selectin, VCAM-1, and sICAM-1, according to previously
reported biomarkers in IPF. In addition, MMP-7 was measured
via ELISA (Fig. 5A). Two out of these six candidate proteins
were significantly regulated during the onset and resolution of
fibrosis when measured by Luminex in plasma: E-selectin was
significantly increased at day 7 and significantly decreased at
day 56 compared with controls, whereas sICAM-1 was signif-
icantly increased from day 7 through day 28, after which levels
normalized again. The increase in circulating sICAM-1 was
validated by ELISA, which showed a significant increase in
sICAM-1 levels at day 14 after bleomycin treatment (Fig. 5C).
Both assays showed similar regulation of sICAM-1, but ELISA
values are well known to underestimate real concentrations
compared with Luminex platforms (7). Interestingly, some of
these candidate proteins were not detectable in BALF in the
same individuals (Fig. 5B). From the six candidate proteins
tested, four were detectable in BALF (MMP-7, MMP-9, sI-
CAM-1, and PAI-1), out which two were significantly in-
creased during fibrosis: PAI-1 was significantly increased ex-
clusively at day 7, whereas MMP-7 was significantly increased
at day 7 and day 14, during the peak of fibrosis.
We correlated the selected protein levels with pulmonary
compliance and analyzed the correlation coefficient of these
two variables within all measured samples. No significant
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Fig. 5. Plasma and BALF biomarker profiling during lung injury and fibrosis. MMP-7 was measured by ELISA and MMP-9, PAI-1, E-selectin, VCAM-1, and
sICAM-1 were measured by Luminex multiplex assay in plasma (A) and BALF (B) samples obtained from bleomycin- or PBS-treated mice over 7, 14, 28, and
56 days. In BALF measurement, VCAM-1 and E-selectin were nondetectable, and “n” vary according to detectability. C: sICAM-1 ELISA using plasma samples
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correlation was observed for MMP-9, and VCAM-1. A weak
but significant correlation was observed for MMP-7, and E-
selectin; and a stronger and highly significant correlation (P 
0.0001) for PAI-1 and sICAM-1 with respect to protein plasma
levels and lung function (Fig. 6).
Compartmentalized regulation of ICAM-1 during lung in-
jury and fibrosis. To further determine whether sICAM-1
blood levels were regulated during the onset and progression of
fibrosis in an intraindividual manner, we performed sequential
bleedings from day 0 to day 15 and measured sICAM-1 levels
every third day in control and bleomycin-treated mice. We
observed that sICAM-1 levels were significantly increased as
fibrosis developed (Fig. 7A). Importantly, Western blotting of
whole lung homogenates revealed that ICAM-1 protein expres-
sion levels were significantly increased at day 14 compared
with PBS controls (Fig. 7B). Immunohistochemical staining
demonstrated that ICAM-1 was strongly expressed in alveolar
epithelial cells and endothelial cells in the healthy lung, and it
was prominently expressed in hyperplastic alveolar epithelial
cells and endothelial cells during fibrosis (Fig. 7D). To confirm
this, we investigated whether sICAM-1 is shed from alveolar
epithelial cells during fibrosis by analyzing supernatants of
primary alveolar epithelial (pmATII) cells from PBS- and
bleomycin-treated mice (day 14). We observed that superna-
tants from bleomycin-treated pmATII cells exhibited signifi-
cantly increased levels of sICAM-1 compared with PBS-
treated pmATII cells (Fig. 7C).
DISCUSSION
We have witnessed an unprecedented gain in our under-
standing of the pathomechanisms driving lung fibrosis in the
past years, including the assessment of mRNA and miRNA
expression patterns in the fibrotic lung, both in murine and
human studies. Two therapies for IPF have recently been
approved in Europe, the United States, and a variety of other
countries (18, 29), both of which decelerate the lung function
decline in patients with IPF. Despite these major achievements,
we are still unable to stop progression, or, better, reverse the
loss of functional lung tissue in IPF (10). The development of
better diagnostic tools and continued efforts for drug develop-
ment in IPF, using better refined and defined animal models
and complex phenotypic assays, therefore continue to be a
major challenge to the scientific community (42). To this end,
we sought to comprehensively assess recently described bio-
markers in IPF in the bleomycin-induced model of lung fibro-
sis, in a compartmentalized manner, to increase the accuracy of
interventions and outcome measures during drug testing.
Although the comparison between the bleomycin-induced
model of pulmonary fibrosis and IPF has been highly contro-
versial (2), recent studies show strong commonalities on dis-
tinct levels, encouraging the continuous use of the model for
preclini (4, 26). In humans, IPF lesions are continuous and
progressive, contributing to permanent and irreversible lung
scarring. In mice, the bleomycin-induced fibrotic lesions are
heterogeneous, time-limited, and self-resolving, bringing the
advantage of analyzing the dynamics of injury-fibrosis-resolu-
tion and assess heterogeneity in an intraindividual manner. At
first, the inflammatory phase takes place within the first 7 days,
followed by increased ECM deposition with a maximum at day
14, and resolution from days 21–28 onward. Largely, lung
function returns to basal levels at 56 days after bleomycin
treatment, as we have previously reported (31).
Importantly, the spatio-temporal heterogeneity of lung fibro-
sis increases the complexity in achieving these goals. Well-
established systematic measurements, such as pulmonary func-
tion tests (e.g., FVC, FEV1), are in daily clinical use to assess
restrictive lung disease, but they remain unspecific and with
limited sensitivity, possibly preventing early detection of pa-
tients with lung fibrosis (32). In addition, only 14% of patients
with early interstitial lung disease exhibit changes in high-
resolution computed tomography (14, 40), whereas 32% of
these patients exhibit changes in transbronchial biopsy (8).
These data strongly suggest that a number of fibrotic lesions, in
particular early lesions, are not detected using a combination of
up-to-date imaging and lung function measurements in the
clinical setting. This notion is supported by the data reported in
our study. We show that in mice, the maximum lung function
decline was observed at day 14 after treatment. Lung function
returned to baseline levels, whereas histological analysis still
demonstrated a significant amount of fibrosis in these individ-
uals, demonstrating the need for specific biomarkers detecting
the presence of tissue fibrosis.
To avoid reader-dependent and region-of-interest selection
bias, we developed a whole-lung, semiautomatized quantifica-
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Fig. 6. Correlation of lung function and plasma biomarkers in lung injury and
fibrosis. Correlation coefficients of lung compliance and plasma levels of
selected candidates (MMP-9, MMP-7, PAI-1, E-selectin, VCAM-1, or sI-
CAM-1) were analyzed for subjects treated with bleomycin after days 7, 14,
28, and 56, and respective PBS controls. Correlations between lung compli-
ance and plasma signatures were determined using Pearson’s correlation
coefficient. Significance of the correlation analysis was set at P  0.05.
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tion system. With this method, we were able to provide a
robust, broader assessment of the affected lung by quantifying
the alveolar space loss during fibrosis. In some severe cases,
alveolar loss went up to 30%, and was maintained over time,
although lung function improved. This might reflect a different
molecular/cellular composition of the lung parenchyma during
the scar formation process. It is important to clarify that both
parameters, lung function and histology, are equally required to
understand a given disease process, because each of them may
reflect different aspects of the disease. In the lung fibrosis
model of adenovirus-mediated overexpression of active TGF-
(6), good correlations between histomorphological, radiologi-
cal, and functional changes were observed (1). Notably, this
model is a progressive and persistent model of fibrosis, sup-
porting that during the peak of fibrosis, but not necessarily
during the initiation or resolution thereof, these parameters
comprehensively assess the disease status of the individual.
Interestingly, we found that single ECM components vary
significantly during the evolution of fibrosis in the lung. For
instance, col1a1 and fn1 were predominantly increased at the
peak of fibrosis (when the lung exhibits maximum stiffness),
whereas other ECM components maintained high expression
levels at all time points, supporting that some ECM members
might be causally responsible for lung function decline, and
therefore critically determine the increased parenchymal stiff-
ness of the lung.
Because physiological measures and histopathology are at
times poor predictors of short- and long-term outcome, we
profiled peripheral blood components as reflectors of the fi-
brotic process. Richards and colleagues (28) recently demon-
strated that patients with IPF display a unique plasma signature
that reflects disease severity (by integrating MMP-7, VCAM-1,
S100A-12, ICAM-1, and IL-8) (28). Thus we selected candi-
date markers with the aim of detecting a characteristic signa-
ture of lung injury, fibrosis, and resolution in the bleomycin
model. We found that sICAM-1 was significantly increased at
day 7 and remained increased as the injury was maintained.
This expression was compartmentally regulated and detected in
the blood, but not BALF. Compartmental regulation of
ICAM-1 is detected in patients with IPF in who levels of
ICAM-1 are higher in the peripheral blood than in BALF (36).
The sICAM-1 has been previously reported as a marker for
epithelial injury in kidney disorders (39) because it is a target
of proteinases that shed it from the cell membrane (11).
Recently, in a cohort of patients that have received lung
transplant with primary graft dysfunction (34), sICAM-1 was
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used as a predictor of mortality, which improved when sI-
CAM-1 was analyzed in combination with other markers (e.g.,
sICAM-1–PAI-1 or sICAM-1–sRAGE). Importantly, in-
creased levels of sICAM-1 in progressive injury have been
reported in other models of lung injury (21). In fact, BALF
levels of sICAM-1 were associated with epithelial dynamics
and transdifferentiation. Although our data do not show a
significant increase in sICAM in the BALF of bleomycin-
treated mice, we show that primary murine ATII cells from
fibrotic mice secrete and/or shed higher levels of sICAM into
the supernatant, demonstrating that lung ATII cells are an
important source of sICAM during injury, fibrosis, and reso-
lution thereof.
Interestingly, ICAM-1 plays a critical role during lung injury
and fibrosis in leukocyte kinetics. In arteries, ICAM-1 does not
increase during the initial injury and fibrotic phase of bleomy-
cin-treated mice. Instead, in venules and capillaries, there is an
increase in its expression, accompanied by an increase in
leukocyte rolling, a phenomenon inhibited by treatment with
anti-ICAM-1 monoclonal antibody (30). Furthermore, block-
age of ICAM-1 via monoclonal antibodies inhibits leukocyte
recruitment, but does not decrease hydroxyproline content or
histopathological fibrosis, and therefore does not attenuate
fibrosis (20). On the other hand, fibrotic ICAM1
/
 mice
exhibit decreased collagen content when compared with litter-
mate controls. Moreover, mice with double knockout for
ICAM-1 and L-selectin show a dramatic reduction in collagen
deposition and fibrosis in response to bleomycin compared
with littermate controls or single-knockout mice (16). Taken
together, these data suggest that ICAM-1 determines the se-
verity in lung fibrosis. Here, we show that not only endothelial
cells, but also alveolar epithelial cells, express abundant
amounts of ICAM-1 during disease, which is actively secreted
to their environment. As such, epithelial ICAM-1, likely with
the help of other adhesion molecules, is a critical contributor to
fibrosis via increased secretion/shedding of ICAM-1 to the
extracellular compartment.
Our data also show that sICAM-1 varies among individuals
during the peak of fibrosis (day 14), yet this variation exhibited
a strong correlation with compliance, reflecting that sICAM-1
can monitor disease severity in mice. In humans, sICAM-1
levels correlate with survival, even better when combined with
other biomarkers. Shijubo and colleagues (35) recently per-
formed repetitive measures of ICAM-1 in four patients with
IPF and one patient with sarcoidosis. They found that in
rapidly declining patients with IPF (albeit n  3), serum levels
of ICAM-1 gradually increased in repetitive visits, when dis-
ease worsened until death within a period of 3–12 mo (35).
Furthermore, Okuda and others (25) recently reported that in
the early phase of acute exacerbations of IPF, ICAM-1 is
increased in patients with IPF and might serve as a predictive
indicator for prognosis. Taken together, these data demonstrate
that, similar to fibrotic mice, ICAM-1 levels might predict
disease severity, exacerbations, and mortality in patients with
IPF.
We initially measured sICAM-1 in a multianalyte, bead-
based assay with the Luminex platform. To corroborate our
findings, we validated the upregulation of sICAM-1 by ELISA,
in which we observed a significant increase in sICAM-1 at day
14. The differences in the concentrations of sICAM-1 using the
Luminex and ELISA assays likely results from multiple factors
attributable to interassay variation, epitope specificity from
manufacturer to manufacturer, dynamic range differences be-
tween fluorescence-based detection and absorbance-based as-
say quantification, all of which are currently debated parame-
ters limiting the area of biomarker research (7).
In summary, our studies demonstrate that ICAM-1 is ex-
pressed in the healthy lung epithelium. During injury and
fibrosis, ICAM-1 is shed and its plasma levels increase, which
correlate well with lung function decline in experimental lung
fibrosis. Plasma levels of sICAM-1 measured at day 9 after the
induction of fibrosis may predict worsening of lung function,
and at the same time, higher levels of sICAM-1 were associ-
ated with increased mortality. These studies indicate that sI-
CAM-1 could be considered as an indicator of ongoing lung
injury and fibrosis and might help to monitor disease progres-
sion and therapeutic responses in preclinical models of fibrosis.
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metabolite imaging study of lung tissue indicates no significant 
effects of pirfenidone on metabolic pathways. Remarkably, 
we found 129 discriminative m/z values which represent clear 
differences between control and treated lungs, the majority of 
which are currently unknown. PCA analysis and heatmap view 
can accurately distinguish control and treated groups. This is the 
first pharmacokinetic study to investigate the tissue distribution 
of orally administered pirfenidone and its related metabolites 
simultaneously in organs without labeling. The combination of 
pharmametabolome with histological features provides detailed 
mapping of drug effects on metabolism as response of heathy 
lung tissue to pirfenidone treatment.
Keywords Pirfenidone · Idiopathic pulmonary fibrosis · 
5-Hydroxymethyl pirfenidone · 5-Carboxy pirfenidone · 
Pharmacokinetics · Pharmacometabolomics · Mass 
spectrometry imaging
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AUC0–∞  Area under the curve from 0 to infinity
Cmax  Maximum concentration
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CID  Collision-induced dissociation
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FTICR  Fourier transform ion cyclotron resonance
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IPF  Idiopathic pulmonary fibrosis
ITO  Indium tin oxide
LC–MS/MS  Liquid chromatography–tandem mass 
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tion-mass spectrometry imaging
Pirfenidone-d5  5-Methyl-N-phenyl-2-1H-pyridone-d5
tmax  Time to maximum concentration
9-AA  9-Aminoacridine
Abstract  Given the importance of pirfenidone as the first 
worldwide-approved drug for idiopathic pulmonary fibro-
sis treatment, its pharmacodynamic properties and the meta-
bolic response to pirfenidone treatment have not been fully 
elucidated. The aim of the present study was to get molecular 
insights of pirfenidone-related pharmacometabolomic response 
using MALDI-FTICR-MSI. Quantitative MALDI-FTICR-MSI 
was carried out for determining the pharmacokinetic properties 
of pirfenidone and its related metabolites 5-hydroxymethyl pir-
fenidone and 5-carboxy pirfenidone in lung, liver and kidney. 
To monitor the effect of pirfenidone administration on endog-
enous cell metabolism, additional in situ endogenous metabo-
lite imaging was performed in lung tissue sections. While pir-
fenidone is highly abundant and delocalized across the whole 
micro-regions of lung, kidney and liver, 5-hydroxymethyl pir-
fenidone and 5-carboxy pirfenidone demonstrate heterogene-
ous distribution patterns in lung and kidney. In situ endogenous 
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive parenchymal lung disease characterized by exagger-
ated extracellular matrix deposition within the lungs in the 
absence of known stimuli (Fernandez and Eickelberg 2012; 
Nalysnyk et al. 2012; Raghu et al. 2011). IPF exhibits the 
worst prognosis of all diffuse parenchymal lung diseases 
with a medium survival after diagnosis of 3–5 years (King 
et al. 2011). Pirfenidone was the first drug approved for IPF 
treatment, initially in the EU and recently in the USA, after 
it was demonstrated that pirfenidone slowed IPF progres-
sion by decreasing FEV1 (forced expiratory volume in 1 s) 
decline in multiple studies (King et al. 2014; Noble et al. 
2011). Although pirfenidone treatment is now routinely and 
often used in clinical practice as a therapeutic strategy for 
IPF, its detailed mechanisms of action have not been fully 
elucidated.
Traditionally, pharmacokinetic studies employ liquid 
chromatography–tandem mass spectrometry (LC–MS/
MS), owing to its high detection and quantification accu-
racy and its capacity to analyze a broad range of sample 
concentrations (Lee and Kerns 1999). However, LC–MS/
MS measurements require extraction of the compounds 
of interest prior to measurement. This introduces a loss of 
spatial information, which is an important factor to con-
sider as compounds may have inhomogeneous distribution 
in tissues (Mouton et al. 2008). In contrast, matrix-assisted 
laser desorption/ionization-mass spectrometry imaging 
(MALDI-MSI) mass spectra are acquired by measuring 
spots, referred to as pixels, in a predefined raster across 
sample tissue sections, resulting in a two-dimensional dis-
tribution map for each measured m/z value. This allows the 
acquisition of spatial expression profiles, while preserv-
ing cellular and molecular integrity, combining the mol-
ecule’s spatial organization with specific histological fea-
tures (Balluff et al. 2011; Norris and Caprioli 2013; Walch 
et al. 2008). Mass spectrometers with high resolving power 
and sub-ppm mass accuracy, such as Fourier transform ion 
cyclotron resonance (FTICR) and orbitrap, allow resolution 
of compound peaks from endogenous species with simi-
lar nominal masses (Castellino et al. 2011; Cornett et al. 
2008; Römpp et al. 2011). These advances broaden MSI’s 
potential for pharmacokinetic and pharmacometabolomic 
studies, which is capable of performing simultaneous com-
pound and endogenous metabolite imaging in the full MS 
scan mode, often without requiring MS/MS experiments 
(Cornett et al. 2008; Römpp et al. 2011).
Here we show for the first time that MALDI-FTICR-MSI 
is a novel platform for determining the pharmacokinetic prop-
erties of pirfenidone and its related metabolites, 5-hydroxym-
ethyl pirfenidone and 5-carboxy pirfenidone. Additionally, to 
gain molecular insight as response of pirfenidone treatment 
in lung tissue, we performed endogenous metabolite imag-
ing analysis to elucidate the drug’s effects on metabolism and 
pathways. The correlation of pharmacological and metabo-
lomic data provides comprehensive information that indicates 
response to drug treatment.
Materials and methods
Animals
Eight- to ten-week-old female C57BL/6N mice were 
obtained from Charles River Laboratories. The experiments 
were performed under strict governmental and international 
guidelines and were approved by the local government for 
the administrative region of Upper Bavaria. The protocol 
was approved by the ethics committee of the regional gov-
ernmental commission for animal protection.
Drug administration and tissue collection
Pirfenidone (Selleckchem, Houston, USA) was dissolved 
in carboxymethyl cellulose (CMC) and administered by 
oral gavage at a dose of 500 mg/kg body weight. Control 
mice received CMC alone. Control and treated animals 
were killed at 10, 30, 45, 60, 90 and 240 min following 
drug administration. Three independent biological repli-
cates were performed for each time point. The liver, kid-
neys and lungs were immediately dissected, snap-frozen in 
liquid nitrogen and stored at −80 °C until sectioned.
Tissue sectioning
Frozen tissues were cut into 12-µm-thick sections at 
−20 °C in a cryo-microtome (Leica CM1950, Leica 
Microsystems, Germany). The left lung lobes (non-inflated) 
were sectioned vertically along the long, flat, frontal plane 
to maximize the anatomical features. The left kidneys were 
sectioned midline. The left liver lobes were sliced in such a 
way to get maximum tissue areas.
The sections were thaw-mounted onto indium tin oxide 
(ITO)-coated MALDI target slides (Bruker Daltonics, Ger-
many) and stored in −80 °C freezer until use. After the tis-
sue sectioning, the MALDI-MSI measurements were per-
formed as soon as possible. The maximum storage time of 
the tissue sections in −80 °C is 2 days.
Quantitative MALDI-FTICR-MSI of pirfenidone 
and related metabolites on lung, kidney and liver 
sections at different time intervals
For quantitative MALDI-MSI analysis of pirfenidone 
and related metabolites, we used a MSI quantification 
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approach, which was adapted from previous publica-
tions (Kallback et al. 2012; Pirman et al. 2013). 5-methyl-
N-phenyl-2-1H-pyridone-d5 (pirfenidone-d5, Santa Cruz 
Biotechnology, Germany) was used as internal standard to 
compensate for ion suppression effects due to the biochem-
ical microenvironment and varying histological structures. 
Briefly, tissue sections were spray-coated with pirfenidone-
d5 internal standard solution (0.1 mmol/L pirfenidone-d5 
in 50 % methanol) using a SunCollect™ automatic sprayer 
(Sunchrom, Friedrichsdorf, Germany). Four layers were 
applied with a flow rate of 5, 15, 30 and 40 µL/min, respec-
tively. Following internal standard application, a 30 mg/mL 
super-DHB matrix (Sigma-Aldrich, Germany) in a mixture 
of 50:50:0.2 methanol:H2O:trifluoroacetic acid (v/v) was 
applied using an automated spray coating machine (Image-
Prep, Bruker Daltonics, Germany) to simultaneously 
extract and crystallize the analytes and internal standard.
To create an absolute quantification calibration curve, 
a 1 mmol/L synthetic pirfenidone stock solution in 50 % 
(v/v) methanol was prepared. The stock solution was seri-
ally diluted with H2O to the following standard concen-
trations: 1, 0.4, 0.1, 0.06, 0.04, 0.01 and 0.005 mmol/L. 
Diluted pirfenidone standard solutions and an H2O blank 
(0.3 µL) were spotted onto control kidney, liver or lung 
tissue sections. The internal pirfenidone-d5 standard and 
super-DHB matrix were homogenously deposited as 
described above.
MALDI-FTICR-MSI (Solarix 7T, Bruker Daltonics, 
Germany) was performed in continuous accumulation of 
selected ions (CASI) mode, which enhanced the low abun-
dance species intensities, allowing for their detection. MSI 
measurements were performed with a 70 µm spatial reso-
lution. Mass spectra were acquired in positive mode using 
100 laser shots at a frequency of 1 kHz. The mass-selective 
quadrupole was set to 186.1 m/z with a window of 130 m/z. 
MALDI-FTICR-MS resolution of the drug peaks (pirfe-
nidone m/z 186.0913, 5-hydroxymethyl pirfenidone m/z 
202.0863 and 5-carboxy pirfenidone m/z 216.0655) was 
between 140,000 and 180,000 analyzed by Bruker Com-
pass Data Analysis 4.2 (Bruker Daltonics, Germany). For 
the identification of pirfenidone, the ions of m/z 186.0913 
were accumulated by MALDI-FTICR-MS using CASI 
mode and fragmented using collision-induced dissociation 
(CID).
MALDI-FTICR-MSI and pharmacokinetic data 
analysis
The acquired spectra were processed using flexImaging 
software v. 4.0 (Bruker Daltonics, Germany). The ana-
lyte signal was normalized to the pirfenidone-d5 internal 
standard signal (MH+ m/z 191.1227) to compensate for ion 
suppression effects. A calibration curve was established 
for each tissue type. Average spotted standard intensity 
was determined and correlated to the standard concentra-
tion over the area of the spot (pmol/mm2). The data were 
displayed as the drug signal intensity plotted against the 
amount of drug per mm2. Subsequently, the appropriate tis-
sue section drug concentrations were calculated based on 
the signal intensity with respect to the calibration curve 
concentration.
For pharmacokinetic analysis, the maximum concentra-
tion (Cmax), time to maximum concentration (tmax), half-life 
(T1/2) and area under the curve from 0 to infinity (AUC0–∞) 
were estimated by non-compartmental analysis using Phoe-
nix® WinNonlin® software v. 6.3 (Pharsight Corp., Cary, 
NC). The elimination rate constant was calculated by linear 
regression from the terminal linear concentrations (last four 
time points). Three biological replicates were performed.
H&E staining and histology
Following the MALDI imaging experiments, the matrix 
was removed with 70 % ethanol. The tissue sections were 
stained with hematoxylin and eosin. Slides were scanned 
with a MIRAX DESK digital slide-scanning system (Carl 
Zeiss MicroImaging, Göttingen, Germany).
MADLI-MSI for endogenous metabolite imaging
Endogenous metabolite imaging was performed on lung tis-
sue following 45-min pirfenidone treatment. Control mice 
received CMC alone. Three independent biological repli-
cates were performed. The matrix solution was prepared by 
dissolving 9-aminoacridine (9-AA) hydrochloride mono-
hydrate matrix (Sigma-Aldrich, Germany) at 10 mg/mL in 
70 % methanol and sprayed by a SunCollect™ automatic 
sprayer (Sunchrom, Friedrichsdorf, Germany). The flow 
rate was performed at 10, 20, 30 and 40 µL/min, respec-
tively, for the first 4 layers. The following 4 layers were 
performed at 40 µL/min. The MALDI-MSI experiments 
were performed on MALDI-FTICR-MS using 50 laser 
shots at a frequency of 500 Hz. Mass imaging data were 
acquired in negative ionization mode with 70 µm spatial 
resolution. Signals from mass range of m/z 50–1000 were 
collected. For identification of metabolites, on tissue MS/
MS analysis was performed by MALDI-FTICR-MS using 
CASI mode. Metabolites were either identified by compar-
ing the observed MS/MS spectra with standard compounds 
or by matching accurate mass with databases (mass accu-
racy ≤3 ppm, METLIN, http://metlin.scripps.edu/; Human 
Metabolome Database, http://www.hmdb.ca/; MassTRIX, 
http://masstrix3.helmholtz-muenchen.de/masstrix3/) (Buck 
et al. 2015; Sun et al. 2014).
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Statistical analysis of endogenous metabolite imaging 
data
The acquired MSI data underwent spectra processing in 
flexImaging. The raw data were normalized against the 
root-mean-square of all data points. The average spectra 
of defined regions of interest were exported as.csv files 
and subsequently processed by MATLAB® R2013a (Math-
works, USA). A self-implemented MATLAB analysis pipe-
line was generated based on the work of McDonnell et al. 
2010 (McDonnell et al. 2010). Baseline correction was 
completed by interpolating between given equally spaced 
intervals (spacing 0.02 Da). Resampling was performed 
using a 0.005 Da step width, and the smoothing operation 
was carried out using a Kaiser window of size 3. Using an 
adapted version of the LIMPIC algorithm (Mantini et al. 
2007), peaks were picked using a minimal peak width of 
0.0005, a noise-threshold of 4 and an intensity threshold 
percentage of 0.01. Isotopes were excluded. To identify sta-
tistically significant differences in m/z values, the peak lists 
were analyzed with the Student’s t test. As a result, a list of 
significantly different metabolites could be achieved with 
the corresponding p ≤ 0.05 and intensity fold change ≥2.
Results
Pirfenidone and related metabolite distribution 
as imaged by MALDI-FTICR-MSI
According to published antifibrotic and pharmacokinetic 
studies of pirfenidone in animal models (Schaefer et al. 
2011), we chose a single oral dose of 500 mg/kg body 
weight pirfenidone in C57BL/6N mice, which enables the 
detection of the low abundant metabolite products of pir-
fenidone. The chemical structures of pirfenidone and the 
two related metabolites, 5-hydroxymethyl pirfenidone 
and 5-carboxy pirfenidone, are shown in Fig. 1. MALDI-
FTICR-MSI was used to perform pharmacokinetic studies 
of pirfenidone, 5-hydroxymethyl pirfenidone and 5-car-
boxy pirfenidone in lung, liver and kidney. Acquired mass 
spectra showed that pirfenidone, 5-hydroxymethyl pirfeni-
done and 5-carboxy pirfenidone were successfully detected 
in positive ion mode with the [M+H]+ ions located at m/z 
186.0913, 202.0863 and 216.0655, respectively (Fig. 2). 
On tissue MS/MS spectrum of the peak 186.0913 con-
firmed the identity of pirfenidone in the dosed lung sections 
(Fig. 3). Figure 4 shows the MSI of pirfenidone, 5-hydrox-
ymethyl pirfenidone and 5-carboxy pirfenidone with cor-
responding histologically stained tissue sections. Pirfeni-
done is abundant across all tissue compartments in lung, 
liver and kidney. In contrast, the two metabolic products 
demonstrate different distribution patterns in both the lung 
and kidney. For example, 5-hydroxymethyl pirfenidone is 
mainly localized along the major bronchi. In kidney, the 
highest abundance of the two metabolites was predomi-
nantly observed in the medulla.
Quantification of pirfenidone and related metabolites 
in different tissue sections
MALDI-MSI quantification was performed to track the 
drug transport into specific organs and tissue compart-
ments. The quantification is based on MSI analysis of the 
treated tissue sections compared with pirfenidone calibra-
tion standards deposited on control tissue sections. All cal-
culations were conducted following normalization to the 
pirfenidone-d5 internal standard signal in order to mini-
mize potential artefacts (Kallback et al. 2012). The pirfe-
nidone concentration was divided by the corresponding 
area of the pixel (pmol/mm2) and plotted against the peak 
intensity to establish a calibration curve. As an example, 
Fig. 5 shows the calibration curve generated for quantifi-
cation study in lung tissue (3 replicates). The data showed 
Fig. 1  Chemical structures of 
pirfenidone, 5-hydroxymethyl 
pirfenidone and 5-carboxy 
pirfenidone
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sufficient linearity and reproducibility for downstream 
analysis. The concentration of pirfenidone in treated tissue 
was calculated by correlating its intensity value to the con-
trol tissue-specific calibration curve. Because of the struc-
tural similarity of 5-hydroxymethyl pirfenidone and 5-car-
boxy pirfenidone to the parent drug, the same calibration 
curve was also used to calculate their concentrations. These 
quantified data were employed for further pharmacokinetic 
analysis.
Pharmacokinetic analysis
The time courses and MSI images of pirfenidone and 
related metabolites, 5-hydroxymethyl pirfenidone and 
5-carboxy pirfenidone, from lung tissue at 10, 30, 45, 60, 
90 and 240 after oral drug administration are shown in 
Fig. 6. The highest concentration was observed for pirfe-
nidone, followed by 5-hydroxymethyl pirfenidone and 
then 5-carboxy pirfenidone. The pharmacokinetic param-
eters were calculated using non-compartmental analysis in 
Phoenix® WinNonlin® v. 6.3. The estimated pharmacoki-
netic parameters of pirfenidone in lung, liver and kidney 
are listed in Table 1. The liver reached its maximum drug 
level at 30 min, followed by kidney and lung at 45 min. In 
addition, the liver showed the highest maximum concen-
tration (Cmax) and the largest area under the curve (AUC), 
which might be a result of the first-pass effect of the drug 
and explain the major gastrointestinal side effects (Kashi-
kar et al. 2014). The degree of drug tissue perfusion was 
ranked as liver, kidney and lung, in descending order. This 
Fig. 2  A typical MALDI-
FTICR-MSI mass spectra 
acquired from the lung tissue. 
Pirfenidone, 5-hydroxymethyl 
pirfenidone and 5-carboxy 
pirfenidone were detected in 
positive mode as [M+H]+ ions 
at m/z 186.0913, 202.0863 and 
216.0655, respectively
Fig. 3  Identification of pirfe-
nidone in dosed lung sections. 
The on tissue MS/MS spectrum 
of pirfenidone (m/z 186.0913) 
shows a clear patten which 
matches the reference pirfeni-
done
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is consistent with degree of blood perfusion associated 
with these organs (Giri et al. 2002). The time of maxi-
mum concentration (tmax) is 30 min in liver, 45 min in lung 
and kidney. The T1/2 is 46 min in liver, 67 min in lung and 
49 min in kidney. These data are comparable with previ-
ous plasma-based pharmacokinetic studies of humans and 
animal model studies by oral administration of pirfenidone 
(tmax: 16–60 min, T1/2: 16–150 min) (Bruss et al. 2004; Shi 
et al. 2007; Wang et al. 2006).
Endogenous metabolite imaging
The administration of drugs can influence cell metabolism 
(Clayton et al. 2006; Ellero-Simatos et al. 2014; Wikoff 
Fig. 4  The distribution of pirfenidone and related metabolites in lung, kidney and liver tissue sections from a mouse, 45 min following oral 
administration. MSI data were acquired with a 70 µm spatial resolution
Fig. 5  Calibration curve of 
pirfenidone for MALDI-MSI 
quantification. As an example, 
a representative image of the 
calibration standard solutions 
of pirfenidone at different 
concentrations spotted onto 
control lung tissue is shown 
here. The calibration curve was 
created based on the intensity 
of the calibration standard peak 
as a function of the concentra-
tion per area (pmol/mm2). Three 
replicates were carried out
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et al. 2013). To investigate the metabolic response to the 
administration of pirfenidone, in situ endogenous metabo-
lite imaging was performed on lung tissue after 45-min 
(tmax) pirfenidone treatment. 9-AA was proven as a matrix 
that exhibits very few matrix-derived interferences in the 
low mass range, achieved high sensitivity and high linearity 
in negative ion mode for a wide range of low molecular 
weight metabolites (Edwards and Kennedy 2005; Miura 
et al. 2010a, b; Shroff et al. 2007). Therefore, in this study, 
we chose 9-AA for the endogenous metabolite imaging 
study, aiming for the simultaneous detection of a variety 
of cellular metabolites, i.e., nucleotide derivatives, central 
Fig. 6  a Time course of pirfenidone and related metabolites, 
5-hydroxymethyl pirfenidone and 5-carboxy pirfenidone, in lung 
tissue by MALDI-FTICR-MSI. Data were acquired from three bio-
logical replicates. Log2 scale is used for y-axis. Error bars indicate 
standard error (3 biological replicates). b MALDI-MSI images of 
lung tissue of pirfenidone (186.0913 ± 0.002 Da) and the two metab-
olites, 5-hydroxymethyl pirfenidone (202.0863 ± 0.002 Da) and 
5-carboxy pirfenidone (216.0655 ± 0.002 Da), at time points 10, 30, 
45, 60, 90 and 240 min following drug administration
208 Histochem Cell Biol (2016) 145:201–211
1 3
metabolic pathway metabolites, redox-related metabolites 
and amino acids. We found 129 discriminative m/z values 
that demonstrate clear differences between treated and con-
trol lungs, the majority of which are currently unknown 
(Supplementary data 1). PCA analysis and heatmap view 
can accurately distinguish between control and treated 
groups (Fig. 7). No significant effects on known metabolic 
pathways could be identified. As examples, nucleotide 
derivatives, glycolysis/gluconeogenesis, citrate cycle and 
redox-related metabolites remain unchanged after adminis-
tration of pirfenidone (Fig. 8).
Discussion
Pharmacometabolomics is an emerging field that aims 
to monitor the effects of compounds on metabolic levels 
(Clayton et al. 2006; Ellero-Simatos et al. 2014; Wikoff 
et al. 2013). In this study, we used a state-of-the-art high 
mass resolution MALDI-FTICR-MSI quantification 
approach to investigate the pharmacokinetic and pharma-
cometabolomic properties of pirfenidone. This is the first 
study to visualize metabolic response to pirfenidone treat-
ment and quantify orally administered pirfenidone and its 
related metabolites simultaneously in the lung and different 
organs without labeling. The data represented no obvious 
effects of pirfenidone on known metabolic pathways under 
physiological conditions. However, we observed alterations 
in 129 masses, indicating a clear response to pirfenidone 
treatment. Although the majority of them are unknown and 
the related mechanisms of actions remain elusive, these 
findings open new aspect for elucidating the metabolic sig-
nature of pirfenidone treatment. Further identification and/
or experimental validation of these masses could provide 
insight into the mechanism of variation in drug response 
and predict treatment outcomes.
The pharmacokinetic parameters demonstrated rapidly 
absorption, metabolism and excretion of pirfenidone. These 
results are consistent with plasma-based pharmacokinetic 
studies in humans and non-clinical species (Bruss et al. 
2004, 2008; Giri et al. 2002; Shi et al. 2007; Wang et al. 
2006). In contrast to previously published studies using 
intravenous pirfenidone administration (Bruss et al. 2008; 
Giri et al. 2002), the use of orally administered pirfenidone 
produces a more appropriate pharmacokinetic result, as 
it most closely resembles the clinical drug administration 
protocol. Moreover, compared with plasma pharmacoki-
netics studies, determining pirfenidone concentrations in 
organs could provide valuable information about drug effi-
cacy and bioavailability.
High-resolution MALDI-FTICR-MSI enabled accurate 
localization of parent drug and its metabolites in various 
tissue types and their associated micro-regions. The two 
metabolic products of pirfenidone demonstrate heteroge-
neous distribution patterns in lung and kidney, whereas the 
parent drug is highly abundant and delocalized across the 
whole micro-regions of lung, kidney and liver. According 
to previous publications, pirfenidone is primarily metabo-
lized by cytochrome P450 (CYPIA2), resulting in a step-
wise formation of 5-hydroxymethyl pirfenidone and 5-car-
boxy pirfenidone (Giri et al. 2002; Schaefer et al. 2011). 
Studies on pirfenidone in experimental animal models 
reported anti-fibrotic activities in tissues, such as lung (Iyer 
et al. 1999), liver (Zhao et al. 2009) and kidney (Miric et al. 
2001). Recently, the anti-fibrotic effects of two pirfeni-
done metabolites, 5-hydroxymethyl pirfenidone and 5-car-
boxy pirfenidone, were demonstrated with WI-38 cells in 
an in vitro lung fibroblast model (Togami et al. 2013). The 
comprehensive spatial distribution map correlates the dif-
ferential biological function of the parent drug and metabo-
lites with histological features, allowing for the elucidation 
of both the drug’s biotransformation route and its mecha-
nism of action.
In conclusion, our results demonstrate that MALDI-MSI 
can be employed to examine drug pharmacokinetic metab-
olism and elimination in multiple organs at a histological 
level. The quantitative analysis of pirfenidone in principal 
organs provides valuable information on both the general 
pharmacokinetic parameters and the micro-regional distri-
bution. In the future, this technology would allow correla-
tion of anti-fibrotic drugs to areas of fibrosis in the lung and 
will potentially unravel anti-remodeling processes in lung 
tissue via drug–metabolite–metabolome correlations.
Table 1  Pharmacokinetic parameters following a single oral pirfeni-
done dose (500 mg/kg) in mice (3 biological replicates)
Cmax and tmax were taken directly from the observed data. T1/2 and 
AUC0–∞ indicate terminal elimination of half-life and area under the 
concentration–time curve from time 0 to infinity, respectively
Organ Cmax (pmol/
mm2)
tmax (min) T1/2 (min) AUC0–∞ 
(min2 pmol/mm2)
Lung 7.36 45 67 658
Liver 19.3 30 46 2563
Kidney 8.29 45 49 959
Fig. 7  a MALDI-FTICR-MSI images of 8 unknown masses, which 
represent clear response after pirfenidone treatment. b PCA accu-
rately distinguishes pirfenidone-treated lung samples from control 
groups. c Heatmap of the 129 discriminative masses which indicates 
clear separation between the control and pirfenidone-treated groups
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Supplementary data 1: List of the 129 discriminative masses which represent clear 
differences between control and treated lungs. 
Decreased after pirfenidone treatment 
m/z Pirfenidone 
treatment 
(45min)_1 
Pirfenidone 
treatment 
(45min)_2 
Pirfenidone 
treatment 
(45min)_3 
Control_1 Control_2 Control_3 p value Ratio  
(treated 
/control) 
66.9960 0 0 0 0.0673 0.1164 0.0551 0.0132 0 
85.5940 0 0 0 0.0593 0.0627 0.0589 0 0 
102.0280 0 0 0 0.0529 0.0641 0.0637 0.0001 0 
109.3560 0 0 0.0759 0.0934 0.1125 0.1048 0.0391 0.24 
109.9940 0 0 0 0.1186 0.1692 0.0573 0.0237 0 
120.6870 0 0 0 0.1174 0.1269 0.114 0 0 
134.6760 0.1151 0.151 0.1602 0.2853 0.3413 0.3642 0.0023 0.43 
152.8520 0 0 0 0.17 0.2001 0.0747 0.0172 0 
154.8500 0.0679 0 0.0615 0.2559 0.291 0.1154 0.0373 0.20 
173.0350 0 0.2259 0.1962 0.336 0.4433 0.3777 0.0341 0.36 
173.5300 0.0906 0.1285 0.1142 0.2117 0.2416 0.2542 0.0017 0.47 
176.8175 0 0 0 0.1171 0.1434 0.0629 0.0104 0 
178.8160 0 0 0.055 0.2041 0.2514 0.107 0.0217 0.10 
180.8670 0.1411 0.0941 0.1118 0.3757 0.5249 0.2783 0.0191 0.29 
182.8650 0.1449 0.0985 0.1126 0.3908 0.5446 0.3031 0.015 0.29 
189.9890 0 0 0.1047 0.2311 0.288 0.3222 0.005 0.12 
194.8360 0.0806 0 0.0563 0.2219 0.2445 0.1405 0.0167 0.23 
42  
196.8340 0.0825 0 0 0.1957 0.2236 0.1302 0.0163 0.15 
198.8310 0 0 0 0.1045 0.1248 0.0656 0.0048 0 
198.8390 0 0 0 0.0823 0.1155 0.0517 0.0107 0 
198.8680 0 0 0 0.1032 0.1803 0.0773 0.0177 0 
198.8780 0.0535 0 0.0542 0.2293 0.2965 0.1527 0.0136 0.16 
200.0020 0 0 0 0.1642 0.1471 0.0528 0.0248 0 
200.8660 0 0 0 0.1173 0.2091 0.0906 0.0179 0 
200.8760 0.0616 0.0537 0.0681 0.2333 0.3265 0.1643 0.0188 0.25 
202.0070 0 0 0 0.0581 0.0656 0.0826 0.0007 0 
202.0130 0.079 0.109 0.0989 0.1732 0.218 0.1982 0.003 0.49 
204.7920 1.0953 0.8674 0.784 1.7203 2.4632 1.4237 0.0418 0.49 
208.7870 0.7221 0.5425 0.4845 1.1409 1.6494 0.9311 0.0431 0.47 
210.7840 0 0 0 0.0753 0.1323 0.0532 0.021 0 
214.7830 0.09 0.0715 0.0942 0.3147 0.463 0.1924 0.0387 0.26 
216.7810 0.0837 0.0722 0.0942 0.3153 0.4681 0.1971 0.0365 0.26 
216.8500 0 0 0 0.1181 0.1344 0.0628 0.0083 0 
225.9160 1.0976 1.0561 0.9206 2.3399 2.9061 2.1052 0.0043 0.42 
227.9140 1.0143 0.994 0.8584 2.2499 2.7844 1.9875 0.0044 0.41 
241.8900 0.2702 0.4238 0.3342 1.0411 1.3198 0.8037 0.0102 0.32 
243.8880 0.3155 0.483 0.3843 1.1696 1.4753 0.9024 0.0103 0.33 
279.0275 0.0557 0.0593 0.0819 0.1467 0.178 0.2128 0.0055 0.37 
283.0760 0 0 0 0.0565 0.1041 0.0514 0.0136 0 
298.7300 0.3216 0.316 0.2031 0.9748 1.2344 0.4981 0.0468 0.31 
Publications originating from this thesis  43 
 
300.7270 0.6235 0.636 0.3987 1.8206 2.2637 0.9986 0.0393 0.33 
302.7250 0.341 0.3515 0.223 1.0378 1.3159 0.537 0.0467 0.32 
304.8760 0.826 0.4295 0.1913 1.4943 1.938 0.963 0.0435 0.33 
306.8780 1.0962 0.6019 0.2703 1.9194 2.4828 1.2658 0.0443 0.35 
307.9910 0 0.0547 0 0.2535 0.2947 0.0899 0.0405 0.09 
308.8750 1.1134 0.6134 0.2734 1.9163 2.4917 1.2697 0.0461 0.35 
312.8750 0 0 0 0.0869 0.1395 0.0506 0.0232 0.00 
320.9330 0 0 0 0.0591 0.1288 0.0704 0.0163 0.00 
328.7260 0.054 0 0 0.1857 0.1658 0.0826 0.0252 0.12 
329.9630 0 0 0 0.26 0.3797 0.1152 0.0302 0 
329.9817 0 0 0 0.0696 0.0898 0.1302 0.0056 0 
330.7220 0 0 0 0.1588 0.155 0.0711 0.011 0 
346.0267 0.1742 0 0 1.0655 1.2344 1.1414 0.0001 0.05 
346.0430 0 0 0 6.0208 6.6161 6.3938 0 0 
346.0750 0 0 1.3397 1.6982 1.8987 1.731 0.042 0.25 
346.0940 0 0.219 0 0.3546 0.4097 0.3418 0.0176 0.20 
346.1045 0.0926 0 0.1256 0.1844 0.217 0.1669 0.0444 0.38 
346.1340 0 0 0 0.0841 0.0801 0.0538 0.0016 0 
346.2430 0 0 0 0.0563 0.0568 0.0614 0 0 
372.0720 0.1859 0.2662 0.8604 1.5521 1.3997 0.8963 0.0438 0.34 
375.8100 0 0 0 0.0625 0.0527 0.0698 0.0002 0 
381.9150 0 0 0 0.0685 0.0581 0.0572 0.0001 0 
384.0170 0 0 0 0.0622 0.082 0.0731 0.0002 0 
44  
384.1275 0 0 0 0.6506 0.7275 0.5459 0.0003 0 
396.8460 0 0 0 0.0542 0.0565 0.0541 0 0 
398.8420 0 0 0 0.0542 0.059 0.0562 0 0 
405.9980 0 0 0 0.61 0.7845 0.6998 0.0002 0 
447.9673 0.2204 0.1655 0.1556 0.705 0.9606 0.475 0.0197 0.25 
449.9620 0.1715 0.1052 0.0983 0.6347 0.9222 0.4196 0.0224 0.19 
468.9260 0.136 0.3221 0.3526 0.4288 0.6392 0.5624 0.0404 0.50 
535.3060 0.1749 0.2507 0.2585 0.4648 0.6439 0.3814 0.0305 0.46 
563.3360 0.0873 0.1253 0.1277 0.2129 0.3088 0.1725 0.05 0.49 
589.3540 0 0 0 0.0656 0.0851 0.0548 0.0015 0 
606.3420 0 0 0 0.0614 0.0867 0.0575 0.0017 0 
625.1900 0 0 0 0.0768 0.1065 0.0698 0.0017 0 
719.4720 0.1591 0 0 2.3521 2.1574 2.0033 0 0.02 
 
Increased after pirfenidone treatment 
m/z Pirfenidone 
treatment 
(45min)_1 
Pirfenidone 
treatment 
(45min)_2 
Pirfenidone 
treatment 
(45min)_3 
Control_1 Control_2 Control_3 p value Ratio  
(treated 
/control) 
83.0090 0.156 0.2267 0.171 0 0 0.0679 0.0066 8.16 
95.3560 0.1952 0.3301 0.2811 0 0 0 0.0024 Inf 
143.0300 0.1474 0.237 0.1971 0 0 0 0.0017 Inf 
143.0330 0.1153 0.2164 0.1812 0 0 0 0.0045 Inf 
153.0190 0.056 0.0927 0.1123 0 0 0 0.0062 Inf 
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165.0100 0.0559 0.0849 0.0719 0 0 0 0.0011 Inf 
168.0140 0.1863 0.2657 0.2065 0.054 0.0529 0.0867 0.0041 3.40 
213.9640 0.9285 0.4855 0.924 0.1728 0.0499 0 0.0106 10.50 
215.9950 0.0866 0.0632 0.0618 0 0 0 0.0009 Inf 
225.9740 0.5178 0.5892 0.5409 0.1622 0.1655 0.3051 0.0028 2.60 
239.9510 0.2519 0.5329 0.469 0.1218 0.1393 0.2226 0.0471 2.59 
250.0395 0.6486 1.2738 1.0511 0.3369 0.4144 0.4729 0.0357 2.43 
253.9875 0.1332 0.1905 0.1769 0 0 0.0733 0.0089 6.83 
256.0600 0.2976 0.3243 0.3511 0.114 0.1437 0.1596 0.0008 2.33 
266.0345 0.5061 0.9102 0.7921 0.2604 0.2819 0.3058 0.0198 2.60 
268.0500 1.5477 2.7412 2.2887 0.534 0.6189 0.8857 0.0141 3.23 
284.0450 8.9457 11.1789 10.2076 2.6939 2.8528 4.1111 0.0009 3.14 
284.0535 0.1851 0.2674 0.2772 0 0.0988 0 0.0088 7.38 
285.9680 0.0748 0.117 0.0753 0 0 0 0.0031 Inf 
286.0405 0.262 0.3795 0.3412 0.1537 0.2112 0.1263 0.0185 2.00 
286.0610 17.6674 22.5029 19.8583 5.1833 5.2234 7.8811 0.0011 3.28 
286.0685 0.7295 0.2248 0.874 0 0 0 0.0363 Inf 
287.0620 1.2352 1.6508 1.4474 0.6291 0.6973 0.5433 0.003 2.32 
288.0560 0.6251 0.8822 0.798 0.3088 0.3954 0.3517 0.0064 2.18 
288.9500 0.0817 0.1767 0.1065 0 0 0 0.0129 Inf 
302.0560 0.1704 0.2325 0.2444 0.0689 0.0772 0 0.0076 4.43 
302.0650 0.1067 0.1831 0.2302 0.0534 0.0613 0 0.0296 4.53 
307.9990 0.0855 0.0951 0.1136 0 0.0507 0.0601 0.0402 2.65 
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318.6500 0.0637 0.0641 0.0922 0 0 0 0.0015 Inf 
318.8890 0.0965 0.0827 0.09 0 0.07 0 0.0486 3.84 
326.0090 0.0938 0.1629 0.1364 0 0 0.0509 0.0123 7.73 
327.1880 0.0913 0.079 0.0525 0 0 0 0.0029 Inf 
341.0110 0.0595 0.1168 0.0854 0 0 0 0.0062 Inf 
342.0040 1.6425 1.698 1.7473 0.5912 0.6268 0.81 0.0002 2.51 
344.0010 0.2715 0.3079 0.2895 0 0.0504 0.0834 0.0008 6.49 
344.0200 4.3667 4.2929 4.086 1.0601 1.0421 1.7145 0.0002 3.34 
345.0220 0.1355 0.1422 0.1391 0.0593 0.0696 0 0.0116 3.23 
357.9780 0.1504 0.3077 0.3212 0.0797 0 0.0878 0.0296 4.65 
358.9555 0.3625 0.4911 0.5065 0.2213 0.2174 0.1621 0.0069 2.26 
359.9915 0.3679 0.6069 0.5594 0.2022 0.1904 0.1878 0.0122 2.64 
361.0835 0.0899 0.0813 0.0786 0 0 0 0 Inf 
361.9900 0.0948 0.1717 0.1583 0 0 0 0.004 Inf 
376.1030 0.1069 0.1348 0.1537 0 0 0 0.0006 Inf 
388.0090 0.8284 1.5169 0.9608 0.2366 0.2493 0.3964 0.0204 3.75 
406.2220 0.1753 0.1928 0.1342 0 0 0 0.0007 Inf 
407.9960 0.1143 0.2015 0.124 0 0 0 0.006 Inf 
416.2060 0.105 0.1097 0.076 0 0 0 0.0008 Inf 
431.0430 0.0673 0.1458 0.0766 0 0 0 0.0175 Inf 
433.0575 0.4448 0.7667 0.4745 0 0.0534 0.1416 0.0109 8.65 
460.2637 0.0869 0.0877 0.0724 0 0 0 0.0001 Inf 
531.2710 0.0553 0.0597 0.0564 0 0 0 0 Inf 
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638.2420 0.2224 0.1776 0.1435 0 0 0 0.0014 Inf 
719.4940 3.2603 1.8352 2.9413 0 0 0 0.0034 Inf 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• The identification of ADP, AMP, GDP, citrate, glutathione and  glutathione 
disulfide were carried out by on tissue MS/MS using MALDI-FTICR. 
• The metabolite standards were purchased from Sigma-Aldrich (Sigma-
Aldrich, Munich, Germany)
• The on tissue MS/MS spectra matched well with the standard metabolites. 
These data indicate the identity of the target metabolites.
Supplementary data 2: On tissue MS/MS data of ADP, AMP, GDP, citrate, 
glutathione and glutathione disulfide.
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3. Discussion
1
  
 
IPF is a lethal disease with a median survival lower that many cancer types. In 
the past decade, we have witnessed an unprecedented increase of 
understanding the mechanisms driving lung fibrosis. The gain of knowledge in 
IPF pathogenesis has moved the field from an untreatable condition with high 
mortality rates, to steady growing potential therapeutic routes.  
Through the implementation of these studies we could: first, determine the 
importance of imaging for subclinical disease detection in mice and detected 
that plasma levels of ICAM1 strongly correlate with disease severity. Second, we 
describe for the first time the matrisome dynamics during initiation, peak and 
resolution of fibrosis. Third, we applied MALDI-FTICR-MSI imaging as detection 
tool for pharmacokinetic and pharmacometabolomic detection of pirfenidone in 
fibrotic and normal mouse lungs. Thus, we develop novel tools and applied 
technologies to better understand IPF and the bleomycin-induced pulmonary 
fibrosis model, in forward and reverse translational approaches 
 
3.1. Compartmentalized assessment of biomarkers in injury and 
repair 
. In translational medical research, mice models are essential for studying 
biological processes in mammalians (Vandamme, 2014). To date, animal 
experiments remain crucial to understand the fundamental mechanisms 
                                               
1 Parts are based on the discussion in [(Fernandez et al., 2016a; Schiller et al., 2015; Sun et al., 
2015; Sun et al., 2018)] 
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underlying the onset of disease and to discover methods to prevent, diagnose 
and treat them (Barre-Sinoussi & Montagutelli, 2015). The comparison between 
mice models and human diseases remains controversial, and possibly will 
continue to be so. Particulary, the bleomycin-induced pulmonary model fibrosis 
and IPF has also been highly debated, it is self-resolving and does not fully 
recapitulate IPF (Tashiro et al., 2017). However, it is currently the best-
characterized and most commonly applied (Jenkins et al., 2017). Many studies 
show strong commonalities on distinct levels, encouraging its continuous use 
for preclinical testing (Bauer et al., 2015; Peng et al., 2013).  
Currently, diagnosis and disease course prediction in idiopathic pulmonary 
fibrosis primarily relies on lung function measures (Erbes et al., 1997). Peripheral 
circulating biomarkers are constantly proposed for diagnosis and outcome, yet 
their correlation with lung function and histology remains unclear 
(Drakopanagiotakis et al., 2018). Here, we comprehensively assessed human-
relevant circulating biomarkers in fibrotic mice and correlated their abundance 
with lung function and histology during the onset, progression, and resolution 
of lung fibrosis. 
We observed that lung function decline is not a prerequisite for histologically 
evident fibrosis, especially in onset and resolution of injury (Fernandez et al., 
2016a). This supports that early micro- and macroscopic changes in the lung 
might precede lung function decline. This seems to be a feature shared between 
mice and humans, where imaging has shown to be the only available tool for 
early disease detection (Washko et al., 2011), in subclinical scenarios before a 
dramatic loss-of-organ function happens (Sack et al., 2017), and can also be 
associated with genetic predisposition (Hunninghake et al., 2013). Furthermore, 
we detected that plasma levels of ICAM1 could determine the severity of lung 
fibrosis in mice. Being sICAM1 the human-relevant marker that provided the 
tighter correlation with lung function decline during the peak of fibrosis in mice. 
We detected that ICAM1 was shed from injured epithelial cells and probably 
Discussion  57 
 
released to the circulation. In IPF, ICAM1 has being shown as marker of disease 
severity (Richards et al., 2012) and acute exacerbations (Okuda et al., 2015), 
reflecting its value in ongoing epithelial injury. Taking together, this data 
demonstrate that in similarity to mice, ICAM1 levels might predict disease 
severity, exacerbations, and mortality in IPF patients.   
Next, we monitored mice from the onset of inflammation and fibrosis to its full 
recovery by a combined analysis of proteome, secretome and transcriptome of 
total lung tissue and broncho alveolar lavage (BAL) (Schiller et al., 2015). Taking 
advantage of the self-regenerative properties of the bleomycin induced-fibrosis 
model, we were first in comprehensively characterizing the lung ECM dynamics 
upon injury and repair.  We perform measurements at day 3 (early 
inflammation), day 7 (late inflammation), day 14 (fibrosis), day 28 (remodeling) 
and day 56 (resolution) (Fernandez et al., 2016a). In the lung tissue, we quantified 
8,019 protein groups, a total of 3,032 of these proteins (154 matrisome 
components), changed significantly in at least one of the time points. To grant 
clinical relevance to the significantly regulated targets in our data, we 
correlated protein abundance with lung compliance for each mouse of the 
study. For instance, Tenascin C abundance showed a negative correlation, 
meaning the more Tenascin C the lower the compliance, therefore the stiffer 
the tissue. In contrast, for Collagen-IVa5, a collagen subunit required for basal 
membrane stability, we observed a positive correlation, reflecting the loss and 
destruction of basal membrane components during fibrosis (Barkauskas & 
Noble, 2014). Furthermore, we revealed novel ECM components that have not 
being described before in the fibrosis-resolution context, as Emilin-2 and 
collagen-XXVIII, which are now relevant targets under study. In conclusion, 
with these studies we provide an extensive, state-of-the-art resource of 
methods and novel molecules for the field of lung injury, repair and 
regeneration.  
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3.2. MALDI imaging: a tool for drug detection and monitoring 
Matrix-Assisted Laser Desorption/Ionization-Mass Spectrometry Imaging 
(MALDI-MSI), with Fourier-Transform Ion Cyclotron Resonance (FTICR) and 
Orbitrap, is the use of matrix-assisted laser desorption ionization as a mass 
spectrometry imaging technique in which the sample, for example a thin tissue 
section, is moved in two dimensions while the mass spectrum is recorded 
(Chaurand et al., 2006). MALDI imaging is a versatile technique that gained 
special interest as a tool to discover and visualize the spatial distribution of 
molecules. Since small molecules ionize easier by MALDI, a high mass accuracy 
and resolution mass spectrometer can be employed such as Fourier-transform 
ion cyclotron resonance (FT-ICR), allowing to make hypotheses on chemical 
formulas directly from the exact masses of the detected peaks. It enables the 
simultaneous mapping of the spatial distribution of a wide range variety of 
analytes such as metabolites, lipids, peptides and proteins (Aichler et al., 2017) 
(Ly et al., 2015). The ability of MALDI imaging to simultaneously record the 
distributions of hundreds of molecules in tissue makes it a powerful discovery 
method for molecular pathology (Balluff et al., 2011). MALDI-MSI combines the 
chemical specificity of modern mass spectrometry with the imaging capabilities 
of microscopy; it allows a highly multiplexed and untargeted analysis of 
biomolecular ions and enables their localization within the tissue section.  
 
3.3. Tools for drug detection and monitoring: Pirfenidone as a 
metabolic regulator in fibrosis 
Pirfenidone is one of the two drugs approved for the treatment of idiopathic 
pulmonary fibrosis (Behr, 2013). Yet, the precise mechanism of action, 
distribution in the lung parenchyma and metabolic effect is largely unknown. 
Here, we used a state-of-the-art technology for in-situ drug detection and 
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imaging, to better understand the dynamic behavior of pirfenidone in the 
normal and fibrotic lung of mice and humans. Initially, we performed high-
resolution quantitative MALDI-FTICR MSI to visualize and quantify orally 
administered pirfenidone and putative metabolites in the lung, together with 
visualizing the in-situ pharmacometabolic response (Sun et al., 2015). As a proof-
of-concept, and to primarily understand the effect in the healthy lung, we orally 
administer pirfenidone in unchallenged mice, in different time points, to assess 
in-situ detection. Although in the -healthy lung, we did not observe an obvious 
effect on known metabolic pathways, we detected significant alterations in 129 
unknown masses, demonstrating an in-situ effect of pirfenidone. 
Pharmacokinetic detection in the blood and multiple organs (e.g. liver, lung and 
kidney) were concordant with studies in plasma of human and other species 
(Bruss et al., 2004; Bruss et al., 2008; Giri et al., 2002; Shi et al., 2007; Wang et al., 
2006).  
In order to understand the significance and impact of pirfenidone treatment in 
mice and human with lung fibrosis, we performed high-resolution MALDI-
FTICR-MSI imaging in bleomycin-induced fibrosis mice and controls, and in 
donor and IPF patients, both treated with pirfenidone and treatment naïve (Sun 
et al., 2018). Our study demonstrates, for the first time, in situ metabolic 
alterations during fibrosis and analyses the pharmacometabolic effect of 
pirfenidone in fibrotic tissue of mice and humans. In detail, we demonstrated an 
increase of pirfenidone and related metabolites in fibrotic tissue. We further 
detected the mass spectra of fibrotic areas, to unequivocally assess metabolite 
detection in specific areas of interest (Figure 8). 
Having a closer look into the distribution of pirfenidone and its putative 
metabolites, we observed that 5-hydroxymethyl pirfenidone (m/z 202.0863) and 
5-carboxy pirfenidone (m/z 216.0655) are more abundant in fibrotic areas with 
higher collagen-1 deposition than in non-fibrotic areas (Figure 7F).  Suggesting 
that the distribution, and possibly the metabolism, of pirfenidone are enhanced 
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in fibrosis and accumulation in affected areas might be required for its anti-
fibrotic effects. For instance, in lung fibroblasts, 5-hydroxymethyl pirfenidone 
and 5-carboxy pirfenidone inhibit TGF-ȕ-induced collagen synthesis, 
demonstrating that pirfenidone metabolites also have anti-fibrotic activities 
(Togami et al., 2013).  
 
Figure7. Pirfenidone detection in bleomycin-induced pulmonary fibrosis mice 
lungs. a) Haematoxylin and Eosin (H&E) staining of sectioned lungs from mice treated 
with phosphate-buffered saline (PBS), PBS+pirfenidone (PBS+PFD), bleomycin to 
induce fibrosis, and bleomycin+pirfenidone (B+PFD). b) Lung compliance 
measurements of mice from each treatment group. Data are shown as mean ± 
standard deviation (SD), and asterisks (*, **, ***) indicate significant differences 
(p≤0.05, 0.01, 0.001, respectively). c) Left panel: mass spectrometry imaging (MSI) 
distribution of pirfenidone and its related metabolites, 5-hydroxymethyl pirfenidone 
and 5-carboxy pirfenidone, in lungs from PBS+PFD and B+PFD-treated mice. Right 
panel: relative quantification of pirfenidone and related metabolites in lungs from 
PBS+PFD and B+PFD-treated mice. d) Heterogeneous distribution pattern of central 
pathway-related endogenous metabolites in lung tissue from B+PFD-treated mice: 
UDP-GlcNAc (UDP-N-acetylglucosamine), G-6-P (glucose-6-phosphate), F-1,6-P 
(fructose-1,6-bisphosphate), glycerol-P (glycerol monophosphate), GSSG (glutathione 
disulphide). e) H&E images with zoomed regions of non-fibrotic and fibrotic tissue are 
illustrated. Spatial segmentation of histological components through unsupervised 
hierarchical clustering reflects the histological components of fibrotic (blue) and non-
fibrotic area (pink). f) Immunofluorescence staining for collagen type 1 in sectioned 
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lungs from the B+PFD-treated group. (Taken from Sun N*, Fernandez IE*, et al., ERJ 
accepted Jul 2018) 
 
Using this technology, we are able to completely dissect metabolic pathways 
and determine their spatial distribution, as well as quantifying the intensity of 
detection. Last, we identified overlapping and exclusive metabolic fingerprints 
that characterize the fibrotic response in human and mice, together with the 
pharmacometabolic response to pirfenidone in fibrosis. For instance, we 
observed an overlapping increase in the ascorbate and aldarate metabolism in 
mice and human during fibrosis. This confirms the enhancement in collagen 
metabolism and production observed in organ fibrosis. In mice, ascorbate and 
aldarate metabolism decreases after pirfenidone treatment. Ascorbate is a 
crucial co-substrate for the enzymes responsible for post-translational 
hydroxylation of prolyl and lysyl residues necessary for rendering the collagen 
triple helix thermostable, as well as, for the extracellular cross-linking of 
collagen fibres (Hata & Senoo, 1989; Murad et al., 1983), which makes it critical 
for collagen synthesis and processing. The enhancement of ascorbate and 
aldarate metabolism during fibrosis, and the decrease upon pirfenidone 
administration, demonstrates the anti-fibrotic effect of pirfenidone. This further 
confirms its effect in collagen processing, supporting its effect in inhibiting 
collagen fibril formation in IPF fibroblast (Knuppel et al., 2017). 
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Figure 8. Pathway analysis of discriminative metabolic alterations in bleomycin-induced 
fibrosis and IPF patients with and without pirfenidone treatment and controls. A) On the 
right, representative images of metabolites reduced in fibrosis: bisphosphoglycerate (m/z 
264.9525), phosphatidic acid (m/z 647.4675). On the left, from top to bottom, representative 
images of metabolites enhanced in fibrosis: ascorbic acid (m/z 175.0250), UDP-N-acetyl-D-
galactosamine (606.0755). B) Relative quantification of metabolites in mice treated with PBS, 
PBS+PFD, bleomycin, and B+PFD. C) On the right, representative images of metabolites reduced 
in IPF: D-myo-Inositoltriphosphate (m/z 418.9565), phosphatidylcholine (m/z 718.5410). On the 
left, from top to bottom, representative images of metabolites enhanced in IPF: 3-Amino-2-
oxopropylphosphate (m/z 168.0070), cyteinyl-glycine (m/z 177.0340). D) Relative quantification 
of the depicted metabolites in donor, IPF, and pirfenidone-treated IPF (IPF+PFD). One-way 
ANOVA was used for statistical analysis, with the Bonferroni post-hoc test. Asterisks (*, **, ***) 
indicate significant differences (p≤0.05, 0.01, 0.001, respectively) between control and treated 
group. (Taken and modified from Sun N*, Fernandez IE*, et al., ERJ accepted Aug 2018). 
 
In order to identify the similarities and differences in regulation of pirfenidone 
in mice and human fibrosis, we performed pathway enrichment analysis. We 
could confirm overlapping and distinctive features in mice and human fibrosis 
(Table 1). As mentioned earlier (chapter 1), it is topic of discussion that 
bleomycin-induced pulmonary fibrosis is a self-resolving, easily manipulated 
model, that does not fully recapitulate IPF (Jenkins et al., 2017).  While other 
studies show shared features on mice and humans fibrosis on different levels, 
supporting its use (Jenkins et al., 2017). The vast knowledge gained in years of 
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studying the bleomycin-induced pulmonary fibrosis model allows us to study 
metabolic effects that occur during early stage pirfenidone treatments. For 
instance, in the lung pirfenidone and its metabolites are detectable maximum 45 
minutes after administration (Sun et al., 2015). We successfully detected an 
increase in pirfenidone and its related drug metabolites in mice fibrotic lungs, 
but not in humans. This effect might be due to the timely controlled 
administration of the drug in mice, a difficult setting to control clinically in pre-
transplanted patients right before their surgical procedure.  Second, pirfenidone 
treatment in mice occurred from disease initiation to peak of fibrosis (d 7-14), 
whereas our IPF cohort was at end-stage disease. Thus, our data may also 
reflect important differences in treatment responses at different disease stages. 
Despite the factors mentioned above, with the introduction of transbronchial 
cryobiopsies for earlier diagnosis of diffuse parenchymal lung diseases (38), 
differences can be minimized, and the applicability of MALDI imaging for 
metabolite profiling or pharmacometabolic drug responses should be 
considered. 
 
 
Table 1. Overlapping and distinctive features of Pirfenidone treatment in human 
and mice. (Taken from Sun N*, Fernandez IE*, et al., ERJ accepted Aug 2018) 
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Among the differentially regulated central metabolic pathways we observed that 
intermediates in glycolysis, nucleotide metabolism, and the pentose phosphate 
pathway are altered in fibrotic regions compared with healthy lungs (Table 1). 
IPF related alterations in glycolysis have been reported previously, acting as 
positive control (Zhao et al., 2017). Dysregulated glycolysis promotes elevated 
lactate levels, thus facilitating disease progression in IPF (Kottmann et al., 2012). 
This metabolic switch towards oxidative pentose phosphate pathway in fibrosis 
might indicate the elevated energy demand and higher energy consumption 
present in fibrosis. Consistent with this, we found lower levels of ATP in IPF 
patients. Similarly, extracellular ATP is decreased in bronchoalveolar lavage fluid 
from IPF samples (Riteau et al., 2010), and others have shown decreased 
intracellular ATP in IPF tissue (Kang et al., 2016), which may result from 
accumulation of dysfunctional mitochondria that promote fibrosis (Bueno et al., 
2015). Collectively, these findings suggest an altered energy household in IPF. 
 
Taken together, these identified alterations in metabolites support the idea that 
metabolic profiles are transformed in regions affected by pulmonary fibrosis. 
The combination of pharmaco- and metabolomics in this study will ultimately 
lead to an improved understanding of disease mechanisms of pulmonary fibrosis 
and mechanism of action of pirfenidone. Moreover, understanding of 
pirfenidone metabolism and the cellular mechanism of action of this drug may 
facilitate the prediction of individual responses to antifibrotic drugs. The label-
free MALDI-MSI technique achieved simultaneous detection, visualization, and 
quantification of both exogenous (drugs and their related metabolites) and 
endogenous metabolites, highlighting compelling competitive advantages over 
traditional analytical techniques. This approach shed light on the spatiotemporal 
behaviours of drugs and endogenous metabolites, and these findings are broadly 
applicable to drug efficacy studies and metabolism of bioactive small molecules 
involved in fibrosis and other pathological conditions 
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4. Conclusions and future directions  
Advances in IPF knowledge show an exciting time ahead, where analysis of the 
genetic makeup and biomarkers will dictate therapeutic approaches, 
subphenotype provide pathway-driven tailored therapies. Hence, implementing 
clinically routine genotyping and biomarker testing is essential for future 
patient stratification and personalized treatment. To address the unmet need 
for effective IPF therapy, a number of new drugs are now being evaluated in 
clinical trials. Interestingly, these drug candidates are targeting three pivotal 
hypothesis of IPF pathophysiology: fibroblasts, ECM, and the immune system.  
Other novel target candidates have been recently revealed, showing once more 
that affecting collagen metabolism might serve as a mechanism to prevent 
continuous ECM remodeling. That is the case of FK506-binding protein 10 
(FKBP10), a collagen chaperone, increased in IPF, and critical for collagen-1 
secretion (Staab-Weijnitz et al., 2015), a potential novel target in IPF that 
deserve further evaluation. Recently, treatment with human recombinant 
Pentraxin 2, a monocyte regulator, showed in a phase 2, randomized, double 
blind, placebo-controlled trial a slower decline in lung function over 28 weeks, -
uncovering a novel therapy for IPF patients (Raghu et al., 2018; van den Blink et 
al., 2016).  
Remarkable efforts form basic, translational and clinical scientists are coming to 
light in an era of growing biomarkers and treatments for IPF. In which, 
biomarker-driven personalized medicine, and combination therapies might be 
required to stop progression, or in best case to reverse disease.  
66  
 
5. References  
Allen, R. J., Porte, J., Braybrooke, R., Flores, C., Fingerlin, T. E., Oldham, J. M., Guillen-
Guio, B., Ma, S. F., Okamoto, T., John, A. E., et al. (2017). Genetic variants 
associated with susceptibility to idiopathic pulmonary fibrosis in people of 
European ancestry: a genome-wide association study. Lancet Respir Med, 5 (11): 
869-880. doi: 10.1016/S2213-2600(17)30387-9. 
Arase, Y., Suzuki, F., Suzuki, Y., Akuta, N., Kobayashi, M., Kawamura, Y., Yatsuji, H., 
Sezaki, H., Hosaka, T., Hirakawa, M., et al. (2008). Hepatitis C virus enhances 
incidence of idiopathic pulmonary fibrosis. World J Gastroenterol, 14 (38): 5880-6. 
Araya, J., Kojima, J., Takasaka, N., Ito, S., Fujii, S., Hara, H., Yanagisawa, H., Kobayashi, K., 
Tsurushige, C., Kawaishi, M., et al. (2013). Insufficient autophagy in idiopathic 
pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol, 304 (1): L56-69. doi: 
10.1152/ajplung.00213.2012. 
Barkauskas, C. E. & Noble, P. W. (2014). Cellular mechanisms of tissue fibrosis. 7. New 
insights into the cellular mechanisms of pulmonary fibrosis. Am J Physiol Cell 
Physiol, 306 (11): C987-96. doi: 10.1152/ajpcell.00321.2013. 
Barre-Sinoussi, F. & Montagutelli, X. (2015). Animal models are essential to biological 
research: issues and perspectives. Future Sci OA, 1 (4): FSO63. doi: 
10.4155/fso.15.63. 
Bauer, Y., Tedrow, J., de Bernard, S., Birker-Robaczewska, M., Gibson, K. F., Guardela, B. 
J., Hess, P., Klenk, A., Lindell, K. O., Poirey, S., et al. (2015). A novel genomic 
signature with translational significance for human idiopathic pulmonary 
fibrosis. Am J Respir Cell Mol Biol, 52 (2): 217-31. doi: 10.1165/rcmb.2013-0310OC. 
Bauer, Y., White, E. S., de Bernard, S., Cornelisse, P., Leconte, I., Morganti, A., Roux, S. & 
Nayler, O. (2017). MMP-7 is a predictive biomarker of disease progression in 
patients with idiopathic pulmonary fibrosis. ERJ Open Res, 3 (1). doi: 
10.1183/23120541.00074-2016. 
Baumgartner, K. B., Samet, J. M., Stidley, C. A., Colby, T. V. & Waldron, J. A. (1997). 
Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir 
Crit Care Med, 155 (1): 242-8. doi: 10.1164/ajrccm.155.1.9001319. 
Baumgartner, K. B., Samet, J. M., Coultas, D. B., Stidley, C. A., Hunt, W. C., Colby, T. V. & 
Waldron, J. A. (2000). Occupational and environmental risk factors for idiopathic 
pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. Am 
J Epidemiol, 152 (4): 307-15. 
Behr, J. (2013). Evidence-based treatment strategies in idiopathic pulmonary fibrosis. 
Eur Respir Rev, 22 (128): 163-8. doi: 10.1183/09059180.00001013. 
Bolanos, A. L., Milla, C. M., Lira, J. C., Ramirez, R., Checa, M., Barrera, L., Garcia-Alvarez, 
J., Carbajal, V., Becerril, C., Gaxiola, M., et al. (2012). Role of Sonic Hedgehog in 
idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol, 303 (11): L978-
90. doi: 10.1152/ajplung.00184.2012. 
Bruss, M. L., Margolin, S. B. & Giri, S. N. (2004). Pharmacokinetics of orally administered 
pirfenidone in male and female beagles. J Vet Pharmacol Ther, 27 (5): 361-7. doi: 
10.1111/j.1365-2885.2004.00612.x. 
References  67 
 
Bruss, M. L., Stanley, S. D., Margolin, S. B. & Giri, S. N. (2008). Pharmacokinetics and 
metabolism of intravenous pirfenidone in sheep. Biopharm Drug Dispos, 29 (2): 
119-26. doi: 10.1002/bdd.595. 
Bueno, M., Lai, Y. C., Romero, Y., Brands, J., St Croix, C. M., Kamga, C., Corey, C., 
Herazo-Maya, J. D., Sembrat, J., Lee, J. S., et al. (2015). PINK1 deficiency impairs 
mitochondrial homeostasis and promotes lung fibrosis. J Clin Invest, 125 (2): 521-
38. doi: 10.1172/JCI74942. 
Camelo, A., Dunmore, R., Sleeman, M. A. & Clarke, D. L. (2014). The epithelium in 
idiopathic pulmonary fibrosis: breaking the barrier. Front Pharmacol, 4: 173. doi: 
10.3389/fphar.2013.00173. 
Carrington, R., Jordan, S., Pitchford, S. C. & Page, C. P. (2018). Use of animal models in 
IPF research. Pulm Pharmacol Ther, 51: 73-78. doi: 10.1016/j.pupt.2018.07.002. 
Catane, R., Schwade, J. G., Turrisi, A. T., 3rd, Webber, B. L. & Muggia, F. M. (1979). 
Pulmonary toxicity after radiation and bleomycin: a review. Int J Radiat Oncol 
Biol Phys, 5 (9): 1513-8. 
Cavazza, A., Rossi, G., Carbonelli, C., Spaggiari, L., Paci, M. & Roggeri, A. (2010). The role 
of histology in idiopathic pulmonary fibrosis: an update. Respir Med, 104 Suppl 1: 
S11-22. doi: 10.1016/j.rmed.2010.03.013. 
Christensen, P. J., Goodman, R. E., Pastoriza, L., Moore, B. & Toews, G. B. (1999). 
Induction of lung fibrosis in the mouse by intratracheal instillation of fluorescein 
isothiocyanate is not T-cell-dependent. Am J Pathol, 155 (5): 1773-9. doi: 
10.1016/S0002-9440(10)65493-4. 
Claussen, C. A. & Long, E. C. (1999). Nucleic Acid recognition by metal complexes of 
bleomycin. Chem Rev, 99 (9): 2797-816. 
Collard, H. R., Calfee, C. S., Wolters, P. J., Song, J. W., Hong, S. B., Brady, S., Ishizaka, A., 
Jones, K. D., King, T. E., Jr., Matthay, M. A., et al. (2010). Plasma biomarker profiles 
in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell 
Mol Physiol, 299 (1): L3-7. doi: 10.1152/ajplung.90637.2008. 
Cool, C. D., Groshong, S. D., Rai, P. R., Henson, P. M., Stewart, J. S. & Brown, K. K. (2006). 
Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast 
reticulum. Am J Respir Crit Care Med, 174 (6): 654-8. doi: 10.1164/rccm.200602-
205OC. 
Cottin, V. & Cordier, J. F. (2012). Velcro crackles: the key for early diagnosis of idiopathic 
pulmonary fibrosis? Eur Respir J, 40 (3): 519-21. doi: 10.1183/09031936.00001612. 
Davis, G. S., Leslie, K. O. & Hemenway, D. R. (1998). Silicosis in mice: effects of dose, 
time, and genetic strain. J Environ Pathol Toxicol Oncol, 17 (2): 81-97. 
Degryse, A. L., Tanjore, H., Xu, X. C., Polosukhin, V. V., Jones, B. R., McMahon, F. B., 
Gleaves, L. A., Blackwell, T. S. & Lawson, W. E. (2010). Repetitive intratracheal 
bleomycin models several features of idiopathic pulmonary fibrosis. Am J Physiol 
Lung Cell Mol Physiol, 299 (4): L442-52. doi: 10.1152/ajplung.00026.2010. 
Desai, O., Winkler, J., Minasyan, M. & Herzog, E. L. (2018). The Role of Immune and 
Inflammatory Cells in Idiopathic Pulmonary Fibrosis. Front Med (Lausanne), 5: 43. 
doi: 10.3389/fmed.2018.00043. 
Drakopanagiotakis, F., Wujak, L., Wygrecka, M. & Markart, P. (2018). Biomarkers in 
idiopathic pulmonary fibrosis. Matrix Biol, 68-69: 404-421. doi: 
10.1016/j.matbio.2018.01.023. 
68  
Epaud, R., Delestrain, C., Louha, M., Simon, S., Fanen, P. & Tazi, A. (2014). Combined 
pulmonary fibrosis and emphysema syndrome associated with ABCA3 mutations. 
Eur Respir J, 43 (2): 638-41. doi: 10.1183/09031936.00145213. 
Erbes, R., Schaberg, T. & Loddenkemper, R. (1997). Lung function tests in patients with 
idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest, 111 
(1): 51-7. 
Evans, W. E., Yee, G. C., Crom, W. R., Pratt, C. B. & Green, A. A. (1982). Clinical 
pharmacology of bleomycin and cisplatin. Drug Intell Clin Pharm, 16 (6): 448-58. 
Fernandez, I. E. & Eickelberg, O. (2012). The impact of TGF-beta on lung fibrosis: from 
targeting to biomarkers. Proc Am Thorac Soc, 9 (3): 111-6. doi: 
10.1513/pats.201203-023AW. 
Fernandez, I. E., Amarie, O. V., Mutze, K., Konigshoff, M., Yildirim, A. O. & Eickelberg, O. 
(2016a). Systematic phenotyping and correlation of biomarkers with lung 
function and histology in lung fibrosis. Am J Physiol Lung Cell Mol Physiol, 310 
(10): L919-27. doi: 10.1152/ajplung.00183.2015. 
Fernandez, I. E., Greiffo, F. R., Frankenberger, M., Bandres, J., Heinzelmann, K., Neurohr, 
C., Hatz, R., Hartl, D., Behr, J. & Eickelberg, O. (2016b). Peripheral blood myeloid-
derived suppressor cells reflect disease status in idiopathic pulmonary fibrosis. 
Eur Respir J, 48 (4): 1171-1183. doi: 10.1183/13993003.01826-2015. 
Fingerlin, T. E., Murphy, E., Zhang, W., Peljto, A. L., Brown, K. K., Steele, M. P., Loyd, J. E., 
Cosgrove, G. P., Lynch, D., Groshong, S., et al. (2013). Genome-wide association 
study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet, 45 
(6): 613-20. doi: 10.1038/ng.2609. 
Flaherty, K. R., Fell, C. D., Huggins, J. T., Nunes, H., Sussman, R., Valenzuela, C., 
Petzinger, U., Stauffer, J. L., Gilberg, F., Bengus, M., et al. (2018). Safety of 
nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. 
Eur Respir J, 52 (2). doi: 10.1183/13993003.00230-2018. 
Giri, S. N., Wang, Q., Xie, Y., Lango, J., Morin, D., Margolin, S. B. & Buckpitt, A. R. (2002). 
Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in 
mice following intravenous administration. Biopharm Drug Dispos, 23 (5): 203-11. 
doi: 10.1002/bdd.311. 
Greene, K. E., King, T. E., Jr., Kuroki, Y., Bucher-Bartelson, B., Hunninghake, G. W., 
Newman, L. S., Nagae, H. & Mason, R. J. (2002). Serum surfactant proteins-A and 
-D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J, 19 (3): 439-46. 
Haston, C. K. & Travis, E. L. (1997). Murine susceptibility to radiation-induced 
pulmonary fibrosis is influenced by a genetic factor implicated in susceptibility 
to bleomycin-induced pulmonary fibrosis. Cancer Res, 57 (23): 5286-91. 
Hata, R. & Senoo, H. (1989). L-ascorbic acid 2-phosphate stimulates collagen 
accumulation, cell proliferation, and formation of a three-dimensional tissuelike 
substance by skin fibroblasts. J Cell Physiol, 138 (1): 8-16. doi: 
10.1002/jcp.1041380103. 
Hu, B., Wu, Z., Bai, D., Liu, T., Ullenbruch, M. R. & Phan, S. H. (2015). Mesenchymal 
deficiency of Notch1 attenuates bleomycin-induced pulmonary fibrosis. Am J 
Pathol, 185 (11): 3066-75. doi: 10.1016/j.ajpath.2015.07.014. 
Hunninghake, G. M., Hatabu, H., Okajima, Y., Gao, W., Dupuis, J., Latourelle, J. C., 
Nishino, M., Araki, T., Zazueta, O. E., Kurugol, S., et al. (2013). MUC5B promoter 
polymorphism and interstitial lung abnormalities. N Engl J Med, 368 (23): 2192-
200. doi: 10.1056/NEJMoa1216076. 
References  69 
 
Hutchinson, J., Fogarty, A., Hubbard, R. & McKeever, T. (2015). Global incidence and 
mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J, 46 
(3): 795-806. doi: 10.1183/09031936.00185114. 
Idiopathic Pulmonary Fibrosis Clinical Research, N., Raghu, G., Anstrom, K. J., King, T. E., 
Jr., Lasky, J. A. & Martinez, F. J. (2012). Prednisone, azathioprine, and N-
acetylcysteine for pulmonary fibrosis. N Engl J Med, 366 (21): 1968-77. doi: 
10.1056/NEJMoa1113354. 
Jenkins, R. G., Simpson, J. K., Saini, G., Bentley, J. H., Russell, A. M., Braybrooke, R., 
Molyneaux, P. L., McKeever, T. M., Wells, A. U., Flynn, A., et al. (2015). 
Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary 
fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet 
Respir Med, 3 (6): 462-72. doi: 10.1016/S2213-2600(15)00048-X. 
Jenkins, R. G., Moore, B. B., Chambers, R. C., Eickelberg, O., Konigshoff, M., Kolb, M., 
Laurent, G. J., Nanthakumar, C. B., Olman, M. A., Pardo, A., et al. (2017). An Official 
American Thoracic Society Workshop Report: Use of Animal Models for the 
Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis. Am J 
Respir Cell Mol Biol, 56 (5): 667-679. doi: 10.1165/rcmb.2017-0096ST. 
Jules-Elysee, K. & White, D. A. (1990). Bleomycin-induced pulmonary toxicity. Clin Chest 
Med, 11 (1): 1-20. 
Kanematsu, T., Kitaichi, M., Nishimura, K., Nagai, S. & Izumi, T. (1994). Clubbing of the 
fingers and smooth-muscle proliferation in fibrotic changes in the lung in 
patients with idiopathic pulmonary fibrosis. Chest, 105 (2): 339-42. 
Kang, Y. P., Lee, S. B., Lee, J. M., Kim, H. M., Hong, J. Y., Lee, W. J., Choi, C. W., Shin, H. K., 
Kim, D. J., Koh, E. S., et al. (2016). Metabolic Profiling Regarding Pathogenesis of 
Idiopathic Pulmonary Fibrosis. J Proteome Res, 15 (5): 1717-24. doi: 
10.1021/acs.jproteome.6b00156. 
Karimi-Shah, B. A. & Chowdhury, B. A. (2015). Forced vital capacity in idiopathic 
pulmonary fibrosis--FDA review of pirfenidone and nintedanib. N Engl J Med, 372 
(13): 1189-91. doi: 10.1056/NEJMp1500526. 
Kendall, R. T. & Feghali-Bostwick, C. A. (2014). Fibroblasts in fibrosis: novel roles and 
mediators. Front Pharmacol, 5: 123. doi: 10.3389/fphar.2014.00123. 
King, T. E., Jr., Pardo, A. & Selman, M. (2011). Idiopathic pulmonary fibrosis. Lancet, 378 
(9807): 1949-61. doi: 10.1016/S0140-6736(11)60052-4. 
King, T. E., Jr., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, 
M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014). A phase 
3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J 
Med, 370 (22): 2083-92. doi: 10.1056/NEJMoa1402582. 
Knuppel, L., Ishikawa, Y., Aichler, M., Heinzelmann, K., Hatz, R., Behr, J., Walch, A., 
Bachinger, H. P., Eickelberg, O. & Staab-Weijnitz, C. A. (2017). A Novel Antifibrotic 
Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril 
Assembly. Am J Respir Cell Mol Biol, 57 (1): 77-90. doi: 10.1165/rcmb.2016-0217OC. 
Kolb, M., Margetts, P. J., Anthony, D. C., Pitossi, F. & Gauldie, J. (2001). Transient 
expression of IL-1beta induces acute lung injury and chronic repair leading to 
pulmonary fibrosis. J Clin Invest, 107 (12): 1529-36. doi: 10.1172/JCI12568. 
Konigshoff, M., Kramer, M., Balsara, N., Wilhelm, J., Amarie, O. V., Jahn, A., Rose, F., Fink, 
L., Seeger, W., Schaefer, L., et al. (2009). WNT1-inducible signaling protein-1 
mediates pulmonary fibrosis in mice and is upregulated in humans with 
idiopathic pulmonary fibrosis. J Clin Invest, 119 (4): 772-87. doi: 10.1172/JCI33950. 
70  
Korfei, M., Ruppert, C., Mahavadi, P., Henneke, I., Markart, P., Koch, M., Lang, G., Fink, 
L., Bohle, R. M., Seeger, W., et al. (2008). Epithelial endoplasmic reticulum stress 
and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care 
Med, 178 (8): 838-46. doi: 10.1164/rccm.200802-313OC. 
Kotsianidis, I., Nakou, E., Bouchliou, I., Tzouvelekis, A., Spanoudakis, E., Steiropoulos, P., 
Sotiriou, I., Aidinis, V., Margaritis, D., Tsatalas, C., et al. (2009). Global impairment 
of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am J 
Respir Crit Care Med, 179 (12): 1121-30. doi: 10.1164/rccm.200812-1936OC. 
Kottmann, R. M., Kulkarni, A. A., Smolnycki, K. A., Lyda, E., Dahanayake, T., Salibi, R., 
Honnons, S., Jones, C., Isern, N. G., Hu, J. Z., et al. (2012). Lactic acid is elevated in 
idiopathic pulmonary fibrosis and induces myofibroblast differentiation via pH-
dependent activation of transforming growth factor-beta. Am J Respir Crit Care 
Med, 186 (8): 740-51. doi: 10.1164/rccm.201201-0084OC. 
Kropski, J. A., Pritchett, J. M., Zoz, D. F., Crossno, P. F., Markin, C., Garnett, E. T., 
Degryse, A. L., Mitchell, D. B., Polosukhin, V. V., Rickman, O. B., et al. (2015). 
Extensive phenotyping of individuals at risk for familial interstitial pneumonia 
reveals clues to the pathogenesis of interstitial lung disease. Am J Respir Crit 
Care Med, 191 (4): 417-26. doi: 10.1164/rccm.201406-1162OC. 
Kropski, J. A., Young, L. R., Cogan, J. D., Mitchell, D. B., Lancaster, L. H., Worrell, J. A., 
Markin, C., Liu, N., Mason, W. R., Fingerlin, T. E., et al. (2017). Genetic Evaluation 
and Testing of Patients and Families with Idiopathic Pulmonary Fibrosis. Am J 
Respir Crit Care Med, 195 (11): 1423-1428. doi: 10.1164/rccm.201609-1820PP. 
Lai, D. M., Shu, Q. & Fan, J. (2016). The origin and role of innate lymphoid cells in the 
lung. Mil Med Res, 3: 25. doi: 10.1186/s40779-016-0093-2. 
Lawson, W. E., Crossno, P. F., Polosukhin, V. V., Roldan, J., Cheng, D. S., Lane, K. B., 
Blackwell, T. R., Xu, C., Markin, C., Ware, L. B., et al. (2008). Endoplasmic 
reticulum stress in alveolar epithelial cells is prominent in IPF: association with 
altered surfactant protein processing and herpesvirus infection. Am J Physiol 
Lung Cell Mol Physiol, 294 (6): L1119-26. doi: 10.1152/ajplung.00382.2007. 
Lee, J. M., Yoshida, M., Kim, M. S., Lee, J. H., Baek, A. R., Jang, A. S., Kim, D. J., Minagawa, 
S., Chin, S. S., Park, C. S., et al. (2018). Involvement of Alveolar Epithelial Cell 
Necroptosis in IPF Pathogenesis. Am J Respir Cell Mol Biol. doi: 
10.1165/rcmb.2017-0034OC. 
Lee, J. S. (2014). The Role of Gastroesophageal Reflux and Microaspiration in Idiopathic 
Pulmonary Fibrosis. Clin Pulm Med, 21 (2): 81-85. 
Lehmann, M., Korfei, M., Mutze, K., Klee, S., Skronska-Wasek, W., Alsafadi, H. N., Ota, C., 
Costa, R., Schiller, H. B., Lindner, M., et al. (2017). Senolytic drugs target alveolar 
epithelial cell function and attenuate experimental lung fibrosis ex vivo. Eur 
Respir J, 50 (2). doi: 10.1183/13993003.02367-2016. 
Lehtonen, S. T., Veijola, A., Karvonen, H., Lappi-Blanco, E., Sormunen, R., Korpela, S., 
Zagai, U., Skold, M. C. & Kaarteenaho, R. (2016). Pirfenidone and nintedanib 
modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary 
fibrosis. Respir Res, 17: 14. doi: 10.1186/s12931-016-0328-5. 
Ley, B., Brown, K. K. & Collard, H. R. (2014). Molecular biomarkers in idiopathic 
pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol, 307 (9): L681-91. doi: 
10.1152/ajplung.00014.2014. 
Li, F. J., Surolia, R., Li, H., Wang, Z., Kulkarni, T., Liu, G., de Andrade, J. A., Kass, D. J., 
Thannickal, V. J., Duncan, S. R., et al. (2017). Autoimmunity to Vimentin Is 
References  71 
 
Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis. J 
Immunol, 199 (5): 1596-1605. doi: 10.4049/jimmunol.1700473. 
Maher, T. M., Oballa, E., Simpson, J. K., Porte, J., Habgood, A., Fahy, W. A., Flynn, A., 
Molyneaux, P. L., Braybrooke, R., Divyateja, H., et al. (2017). An epithelial 
biomarker signature for idiopathic pulmonary fibrosis: an analysis from the 
multicentre PROFILE cohort study. Lancet Respir Med, 5 (12): 946-955. doi: 
10.1016/S2213-2600(17)30430-7. 
Moeller, A., Gilpin, S. E., Ask, K., Cox, G., Cook, D., Gauldie, J., Margetts, P. J., Farkas, L., 
Dobranowski, J., Boylan, C., et al. (2009). Circulating fibrocytes are an indicator 
of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 
179 (7): 588-94. doi: 10.1164/rccm.200810-1534OC. 
Moore, B. B. & Hogaboam, C. M. (2008). Murine models of pulmonary fibrosis. Am J 
Physiol Lung Cell Mol Physiol, 294 (2): L152-60. doi: 10.1152/ajplung.00313.2007. 
Murad, S., Tajima, S., Johnson, G. R., Sivarajah, S. & Pinnell, S. R. (1983). Collagen 
synthesis in cultured human skin fibroblasts: effect of ascorbic acid and its 
analogs. J Invest Dermatol, 81 (2): 158-62. 
Nalysnyk, L., Cid-Ruzafa, J., Rotella, P. & Esser, D. (2012). Incidence and prevalence of 
idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev, 21 (126): 
355-61. doi: 10.1183/09059180.00002512. 
Neighbors, M., Cabanski, C. R., Ramalingam, T. R., Sheng, X. R., Tew, G. W., Gu, C., Jia, G., 
Peng, K., Ray, J. M., Ley, B., et al. (2018). Prognostic and predictive biomarkers for 
patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc 
assessment of the CAPACITY and ASCEND trials. Lancet Respir Med, 6 (8): 615-
626. doi: 10.1016/S2213-2600(18)30185-1. 
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., 
King, T. E., Jr., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011). Pirfenidone in 
patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. 
Lancet, 377 (9779): 1760-9. doi: 10.1016/S0140-6736(11)60405-4. 
Nogee, L. M., Dunbar, A. E., 3rd, Wert, S. E., Askin, F., Hamvas, A. & Whitsett, J. A. (2001). 
A mutation in the surfactant protein C gene associated with familial interstitial 
lung disease. N Engl J Med, 344 (8): 573-9. doi: 10.1056/NEJM200102223440805. 
Noth, I., Zhang, Y., Ma, S. F., Flores, C., Barber, M., Huang, Y., Broderick, S. M., Wade, M. 
S., Hysi, P., Scuirba, J., et al. (2013). Genetic variants associated with idiopathic 
pulmonary fibrosis susceptibility and mortality: a genome-wide association 
study. Lancet Respir Med, 1 (4): 309-317. doi: 10.1016/S2213-2600(13)70045-6. 
Okuda, R., Matsushima, H., Aoshiba, K., Oba, T., Kawabe, R., Honda, K. & Amano, M. 
(2015). Soluble intercellular adhesion molecule-1 for stable and acute phases of 
idiopathic pulmonary fibrosis. Springerplus, 4: 657. doi: 10.1186/s40064-015-
1455-z. 
Oldham, J. M., Ma, S. F., Martinez, F. J., Anstrom, K. J., Raghu, G., Schwartz, D. A., Valenzi, 
E., Witt, L., Lee, C., Vij, R., et al. (2015). TOLLIP, MUC5B, and the Response to N-
Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am J 
Respir Crit Care Med, 192 (12): 1475-82. doi: 10.1164/rccm.201505-1010OC. 
Patel, A. S., Lin, L., Geyer, A., Haspel, J. A., An, C. H., Cao, J., Rosas, I. O. & Morse, D. 
(2012). Autophagy in idiopathic pulmonary fibrosis. PLoS One, 7 (7): e41394. doi: 
10.1371/journal.pone.0041394. 
Peljto, A. L., Zhang, Y., Fingerlin, T. E., Ma, S. F., Garcia, J. G., Richards, T. J., Silveira, L. J., 
Lindell, K. O., Steele, M. P., Loyd, J. E., et al. (2013). Association between the 
72  
MUC5B promoter polymorphism and survival in patients with idiopathic 
pulmonary fibrosis. JAMA, 309 (21): 2232-9. doi: 10.1001/jama.2013.5827. 
Peng, R., Sridhar, S., Tyagi, G., Phillips, J. E., Garrido, R., Harris, P., Burns, L., Renteria, L., 
Woods, J., Chen, L., et al. (2013). Bleomycin induces molecular changes directly 
relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS One, 
8 (4): e59348. doi: 10.1371/journal.pone.0059348. 
Poletti, V., Ravaglia, C. & Tomassetti, S. (2014). Pirfenidone for the treatment of 
idiopathic pulmonary fibrosis. Expert Rev Respir Med, 8 (5): 539-45. doi: 
10.1586/17476348.2014.915750. 
Prasse, A., Probst, C., Bargagli, E., Zissel, G., Toews, G. B., Flaherty, K. R., Olschewski, M., 
Rottoli, P. & Muller-Quernheim, J. (2009). Serum CC-chemokine ligand 18 
concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir 
Crit Care Med, 179 (8): 717-23. doi: 10.1164/rccm.200808-1201OC. 
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z. & Oster, G. (2006). Incidence and 
prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 174 (7): 
810-6. doi: 10.1164/rccm.200602-163OC. 
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., 
Cordier, J. F., Flaherty, K. R., Lasky, J. A., et al. (2011). An official 
ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based 
guidelines for diagnosis and management. Am J Respir Crit Care Med, 183 (6): 
788-824. doi: 10.1164/rccm.2009-040GL. 
Raghu, G., Chen, S. Y., Yeh, W. S., Maroni, B., Li, Q., Lee, Y. C. & Collard, H. R. (2014). 
Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and 
older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med, 2 (7): 566-
72. doi: 10.1016/S2213-2600(14)70101-8. 
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A., Azuma, A., Behr, J., Brozek, J. L., 
Collard, H. R., Cunningham, W., Homma, S., et al. (2015). An Official 
ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic 
Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J 
Respir Crit Care Med, 192 (2): e3-19. doi: 10.1164/rccm.201506-1063ST. 
Raghu, G., van den Blink, B., Hamblin, M. J., Brown, A. W., Golden, J. A., Ho, L. A., 
Wijsenbeek, M. S., Vasakova, M., Pesci, A., Antin-Ozerkis, D. E., et al. (2018). Effect 
of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital 
Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical 
Trial. JAMA, 319 (22): 2299-2307. doi: 10.1001/jama.2018.6129. 
Rajchgot, J., Stanbrook, M. B. & Anand, A. (2018). Combination Nintedanib and 
Pirfenidone for Treatment of Idiopathic Pulmonary Fibrosis. Am J Respir Crit 
Care Med. doi: 10.1164/rccm.201805-0954LE. 
Richards, T. J., Kaminski, N., Baribaud, F., Flavin, S., Brodmerkel, C., Horowitz, D., Li, K., 
Choi, J., Vuga, L. J., Lindell, K. O., et al. (2012). Peripheral blood proteins predict 
mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 185 (1): 67-
76. doi: 10.1164/rccm.201101-0058OC. 
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., 
Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014). Efficacy and safety of 
nintedanib in idiopathic pulmonary fibrosis. N Engl J Med, 370 (22): 2071-82. doi: 
10.1056/NEJMoa1402584. 
Riteau, N., Gasse, P., Fauconnier, L., Gombault, A., Couegnat, M., Fick, L., Kanellopoulos, 
J., Quesniaux, V. F., Marchand-Adam, S., Crestani, B., et al. (2010). Extracellular 
References  73 
 
ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. 
Am J Respir Crit Care Med, 182 (6): 774-83. doi: 10.1164/rccm.201003-0359OC. 
Rosas, I. O., Richards, T. J., Konishi, K., Zhang, Y., Gibson, K., Lokshin, A. E., Lindell, K. O., 
Cisneros, J., Macdonald, S. D., Pardo, A., et al. (2008). MMP1 and MMP7 as 
potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS 
Med, 5 (4): e93. doi: 10.1371/journal.pmed.0050093. 
Sack, C. S., Doney, B. C., Podolanczuk, A. J., Hooper, L. G., Seixas, N. S., Hoffman, E. A., 
Kawut, S. M., Vedal, S., Raghu, G., Barr, R. G., et al. (2017). Occupational 
Exposures and Subclinical Interstitial Lung Disease. The MESA (Multi-Ethnic 
Study of Atherosclerosis) Air and Lung Studies. Am J Respir Crit Care Med, 196 
(8): 1031-1039. doi: 10.1164/rccm.201612-2431OC. 
Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D. & Kossen, K. (2011). Antifibrotic 
activities of pirfenidone in animal models. Eur Respir Rev, 20 (120): 85-97. doi: 
10.1183/09059180.00001111. 
Schiller, H. B., Fernandez, I. E., Burgstaller, G., Schaab, C., Scheltema, R. A., 
Schwarzmayr, T., Strom, T. M., Eickelberg, O. & Mann, M. (2015). Time- and 
compartment-resolved proteome profiling of the extracellular niche in lung 
injury and repair. Mol Syst Biol, 11 (7): 819. doi: 10.15252/msb.20156123. 
Seibold, M. A., Wise, A. L., Speer, M. C., Steele, M. P., Brown, K. K., Loyd, J. E., Fingerlin, 
T. E., Zhang, W., Gudmundsson, G., Groshong, S. D., et al. (2011). A common 
MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med, 364 (16): 
1503-12. doi: 10.1056/NEJMoa1013660. 
Selman, M., Pardo, A. & Kaminski, N. (2008). Idiopathic pulmonary fibrosis: aberrant 
recapitulation of developmental programs? PLoS Med, 5 (3): e62. doi: 
10.1371/journal.pmed.0050062. 
Shi, S., Wu, J., Chen, H., Chen, H., Wu, J. & Zeng, F. (2007). Single- and multiple-dose 
pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese 
volunteers. J Clin Pharmacol, 47 (10): 1268-76. doi: 10.1177/0091270007304104. 
Sime, P. J., Xing, Z., Graham, F. L., Csaky, K. G. & Gauldie, J. (1997). Adenovector-
mediated gene transfer of active transforming growth factor-beta1 induces 
prolonged severe fibrosis in rat lung. J Clin Invest, 100 (4): 768-76. doi: 
10.1172/JCI119590. 
Simonian, P. L., Roark, C. L., Wehrmann, F., Lanham, A. K., Diaz del Valle, F., Born, W. K., 
O'Brien, R. L. & Fontenot, A. P. (2009). Th17-polarized immune response in a 
murine model of hypersensitivity pneumonitis and lung fibrosis. J Immunol, 182 
(1): 657-65. 
Simonian, P. L., Wehrmann, F., Roark, C. L., Born, W. K., O'Brien, R. L. & Fontenot, A. P. 
(2010). gammadelta T cells protect against lung fibrosis via IL-22. J Exp Med, 207 
(10): 2239-53. doi: 10.1084/jem.20100061. 
Song, J. W., Do, K. H., Jang, S. J., Colby, T. V., Han, S. & Kim, D. S. (2013). Blood 
biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary 
fibrosis. Chest, 143 (5): 1422-1429. doi: 10.1378/chest.11-2735. 
Spagnolo, P., Del Giovane, C., Luppi, F., Cerri, S., Balduzzi, S., Walters, E. H., D'Amico, R. 
& Richeldi, L. (2010). Non-steroid agents for idiopathic pulmonary fibrosis. 
Cochrane Database Syst Rev (9): CD003134. doi: 
10.1002/14651858.CD003134.pub2. 
Staab-Weijnitz, C. A., Fernandez, I. E., Knuppel, L., Maul, J., Heinzelmann, K., Juan-
Guardela, B. M., Hennen, E., Preissler, G., Winter, H., Neurohr, C., et al. (2015). 
74  
FK506-Binding Protein 10, a Potential Novel Drug Target for Idiopathic 
Pulmonary Fibrosis. Am J Respir Crit Care Med, 192 (4): 455-67. doi: 
10.1164/rccm.201412-2233OC. 
Stuart, B. D., Choi, J., Zaidi, S., Xing, C., Holohan, B., Chen, R., Choi, M., Dharwadkar, P., 
Torres, F., Girod, C. E., et al. (2015). Exome sequencing links mutations in PARN 
and RTEL1 with familial pulmonary fibrosis and telomere shortening. Nat Genet, 
47 (5): 512-7. doi: 10.1038/ng.3278. 
Sun, N., Fernandez, I. E., Wei, M., Wu, Y., Aichler, M., Eickelberg, O. & A., W. (2015). 
Pharmacokinetic and pharmacometabolomic study of pirfenidone in normal 
mice tissues using high mass resolution MALDI-FTICR-mass spectrometry 
imaging. Histochemistry and Cell Biology. 
Sun, N., Fernandez, I. E., Wei, M., Witting, M., Aichler, M., Feuchtinger, A., Burgstaller, 
G., Verleden, S. E., Schmitt-Kopplin, P., Eickelberg, O., et al. (2018). 
Pharmacometabolic response to pirfenidone in pulmonary fibrosis detected by 
MALDI-FTICR-MSI. Eur Respir J. doi: 10.1183/13993003.02314-2017. 
Tang, Y. W., Johnson, J. E., Browning, P. J., Cruz-Gervis, R. A., Davis, A., Graham, B. S., 
Brigham, K. L., Oates, J. A., Jr., Loyd, J. E. & Stecenko, A. A. (2003). Herpesvirus 
DNA is consistently detected in lungs of patients with idiopathic pulmonary 
fibrosis. J Clin Microbiol, 41 (6): 2633-40. 
Tashiro, J., Rubio, G. A., Limper, A. H., Williams, K., Elliot, S. J., Ninou, I., Aidinis, V., 
Tzouvelekis, A. & Glassberg, M. K. (2017). Exploring Animal Models That Resemble 
Idiopathic Pulmonary Fibrosis. Front Med (Lausanne), 4: 118. doi: 
10.3389/fmed.2017.00118. 
Togami, K., Kanehira, Y. & Tada, H. (2013). Possible involvement of pirfenidone 
metabolites in the antifibrotic action of a therapy for idiopathic pulmonary 
fibrosis. Biol Pharm Bull, 36 (10): 1525-7. 
Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Jr., Lynch, D. A., Nicholson, A. G., 
Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013). An official 
American Thoracic Society/European Respiratory Society statement: Update of 
the international multidisciplinary classification of the idiopathic interstitial 
pneumonias. Am J Respir Crit Care Med, 188 (6): 733-48. doi: 
10.1164/rccm.201308-1483ST. 
Tzouvelekis, A., Herazo-Maya, J. D., Slade, M., Chu, J. H., Deiuliis, G., Ryu, C., Li, Q., 
Sakamoto, K., Ibarra, G., Pan, H., et al. (2017). Validation of the prognostic value of 
MMP-7 in idiopathic pulmonary fibrosis. Respirology, 22 (3): 486-493. doi: 
10.1111/resp.12920. 
van den Blink, B., Dillingh, M. R., Ginns, L. C., Morrison, L. D., Moerland, M., Wijsenbeek, 
M., Trehu, E. G., Bartholmai, B. J. & Burggraaf, J. (2016). Recombinant human 
pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, 
pharmacokinetics and exploratory efficacy. Eur Respir J, 47 (3): 889-97. doi: 
10.1183/13993003.00850-2015. 
Vandamme, T. F. (2014). Use of rodents as models of human diseases. J Pharm Bioallied 
Sci, 6 (1): 2-9. doi: 10.4103/0975-7406.124301. 
Wang, Y., Zhao, X., Zhong, J., Chen, Y., Liu, X. & Wang, G. (2006). Simple determination 
of pirfenidone in rat plasma via high-performance liquid chromatography. 
Biomed Chromatogr, 20 (12): 1375-9. doi: 10.1002/bmc.708. 
Washko, G. R., Hunninghake, G. M., Fernandez, I. E., Nishino, M., Okajima, Y., Yamashiro, 
T., Ross, J. C., Estepar, R. S., Lynch, D. A., Brehm, J. M., et al. (2011). Lung volumes 
References  75 
 
and emphysema in smokers with interstitial lung abnormalities. N Engl J Med, 
364 (10): 897-906. doi: 10.1056/NEJMoa1007285. 
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S. & Kolb, M. 
(2015). Mode of action of nintedanib in the treatment of idiopathic pulmonary 
fibrosis. Eur Respir J, 45 (5): 1434-45. doi: 10.1183/09031936.00174914. 
Wynn, T. A. & Vannella, K. M. (2016). Macrophages in Tissue Repair, Regeneration, and 
Fibrosis. Immunity, 44 (3): 450-462. doi: 10.1016/j.immuni.2016.02.015. 
Yokoyama, A., Kondo, K., Nakajima, M., Matsushima, T., Takahashi, T., Nishimura, M., 
Bando, M., Sugiyama, Y., Totani, Y., Ishizaki, T., et al. (2006). Prognostic value of 
circulating KL-6 in idiopathic pulmonary fibrosis. Respirology, 11 (2): 164-8. doi: 
10.1111/j.1440-1843.2006.00834.x. 
Zhao, Y. D., Yin, L., Archer, S., Lu, C., Zhao, G., Yao, Y., Wu, L., Hsin, M., Waddell, T. K., 
Keshavjee, S., et al. (2017). Metabolic heterogeneity of idiopathic pulmonary 
fibrosis: a metabolomic study. BMJ Open Respiratory Research, 4 (1). doi: 
10.1136/bmjresp-2017-000183. 
76  
Acknowledgments  
The work compiled in this thesis becomes a reality only with the help and 
support of many. It takes a village! Thanks God for showing me the right path, 
putting me at the right time, with the right people, and giving me the endurance 
to climb the ladder even higher.  
To Prof. Dr. Oliver Eickelberg, this work would have not being possible without 
your guidance, support and constant advice, from the first until the last day.  
I would like to thank Prof. Dr. Jürgen Behr and the committee members, for 
evaluating my work and participating in my PhD examination.Special thanks go 
to all collaboration partners and co-authors of the manuscripts part of this 
thesis. 
I am deeply grateful to all of those from the “Eickelberg lab” that came, left, and 
stayed through all these years, with whom I had the pleasure to work, learn, live 
and laugh. For the fun and support, deep thanks go to Kathy and Natalia; as well 
as to Gerald and Claudia. Especial thanks go to Kathy and Adrian for the editing 
and proofing, even last minute. I owe deep thanks to Daniela, Constanze, 
Katharina and Markus for the technical assistance during the long days of 
animal work. It is a great pleasure to thank my team, Flavia and Daniela for 
sharing all those years of work together and the new members of the growing 
crew Dibora, Ivette and Valeria. Special thanks to PD Dr. Anne Hilgendorff for 
her support in the endeavors to come.  
Nobody has been more important to me in pursuing my career than my family. 
To my parents, they developed on me the thirst for learning, and showed me 
that perseverance and endurance comes from passion. Most importantly, to 
Malte for being unconditional, keeping me up and supporting every step I take, 
and of course, to my best gifts, Aleph and Quentin who taught me the true value 
of life. 
